The Journal of the American Diabetes Association

diabetes

lume 10: 1961

INDEX

By Subject and Author

116951

and nephropathy, °160
transitory, 447

ALBUSTIX TEST, °241

ALCOHOL
and hypoglycemia in children, °238
individual response, 197

ALDOLASE
and fructose metabolism, 219, 262
and sorbitol metabolism, 218, 219

ALDOSTERONE
and carbohydrate metabolism, °494
excretion in episodic hyperkalemic paralysis, 456
secretion, and body position in pregnancy, 195

ALLERGY, insulin, and anaphylactic shock, 105-109

ALLOXAN. *See* Diabetes mellitus, alloxan-induced

ALPHA-KETOISOCAPROIC ACID and hypoglycemia, °242, °330

AMERICAN DIABETES ASSOCIATION
Affiliate Associations, 497
Detection Drives, 251
news, 83, 165, 251-252, 337-338, 419, 500
Annual Banquet, 409
highlights, 245, 409
annual meetings
Twenty-first, 163-164, 245-252, 408-414
Annual Session of Delegates, 408
business, 246, 410-414
Bylaws amended, 337
elections, 335, 496-497
Executive Director's report, 412-413
registration figures, 335
scientific sessions, 80, 245-249, 408
Secretary's report, 411-412
special sessions, 246, 408-409
Treasurer's report, 412
Twenty-second, 249, 418, 495-496
new procedure for submission of abstracts, 496
Banting Memorial Lecture, 421-431
Medal, 409
Board of State Governors, 496-497
Committees (1961-62), 497-498
Diabetes Week, 82, 165, 251, 337, 419
essay contest, 82, 417, 496
1960-61 winners, 417
FORECAST
"Are Diabetics Good Life Insurance Risks?" 82
Endocrine Gland Series, 250
Summer Camps for Diabetic Children, 164-165
International Diabetes Federation Fourth Congress, 80-82, 164
delegates, 250
Journal
AMA to abstract from, 164
Editorials
Humoral Nature of Hypoglycemic Factor of Muscular Work, 232-234
Hypoglycemic Insulin Reactions without Warning Symptoms, 151-152
Newer Concepts of Atherosclerosis, 396-397
Phenformin and Ketoacidosis, 321-322
Why Join the American Diabetes Association? 487-488
new procedure for abstract submission, 496
special subscription rates, 82
Lilly award, 164, 250, 336, 409, 418, 499
In memoriam
Bertram, Ferdinand, 324-325
necrology, 84, 166, 252, 338, 420, 500
new members, 82, 165, 251, 337, 499-500
News Notes, 83, 165, 252, 338, 419-420, 500
personals, 84, 166, 252, 338, 420, 500
postgraduate programs, 84, 164, 166, 249, 252, 336, 415-417, 420, 495
registration breakdown, 249
publications
binders available, 82, 251
Diabetic Diet Card for Physicians, 82
Everyday Problems in Diabetes, 418
Meal Planning with Exchange Lists, 82
membership directory, 164, 250, 499
research fellowships, 250, 336, 418
scientific programs
exhibits, 250-251, 418
text available for "Everyday Problems in Diabetes: 201 Crystal Clear Answers," 418
list of papers, 246-249

AMINO ACID
cerebral levels, and oral hypoglycemics, °400
in human and pork insulin, °402
hydrocortisone mobilization, °329
and hypoglycemia, °242
infantile, °72
leucine-induced, °330
individual needs, 197
insulin effects, 428
and exercise, 289
and lipid mobilizer hormone response, 177
and protein catabolism, °329
urinary excretion, °402
in fructosuria, 261

P-AMINOBENZENE-SULFAMIDO-ISOPROPYL-THIODIAZOL, 124-125

P-AMINOBENZENE-SULFAMIDO-TERTIOBUTYL-THIODIAZOL, 124-125

AMPUTATIONS, transmetatarsal, °407

AMYLOIDOSIS, °327

ANAPHYLACTIC SHOCK, 105-109

ANEMIA
and dietary cholesterol, °331
nonspherocytic hemolytic, 260, 266
pernicious, in atrophic gastritis, °338

ANESTHESIA, °155
and blood glucose, °158
and carbohydrate metabolism, °157

ANEURYSMS. *See* Microaneurysms

ANGINA PECTORIS
in arteriosclerotic heart disease, 117
and hypoglycemia, 118

ANOREXIA, °244
and glucagon, °405
after metahexamide, °401

ANTIBODIES
to galactosyl-protein conjugates, °325
glucagon, °494
insulin, °79
and adrenocortical hormones, °73
and anaphylactic shock, 106-107
and cortisone, 112
Crystalline, 107, 144-145, °398
and fluorescein isothiocyanate, 143-147
hemagglutination method, 4, 144-147
and hypoglycemia, °74, °79
and hypophyseal stalk section, 111-113
species specificity, °332, 339

ANTICOAGULANTS
lethal potentialities, 109
in myocardial infarction, °404

ANTITHYROID DRUGS, fatal reactions, 109

AORTA, atherogenic effects
of free diet, °240
and heart disease, 115-117
hypothalamic stimulation, 217
of lactose, 189
of sucrose, 189

APPETITE
adaptation, °73
leucine-induced depression and insulin, °333
and phenmetrazine, °328
after tolbutamide therapy, °406

D-ARABINOSE, intracellular transport and insulin, 423-425

ARTERIOLES, wall thickening, 254
hyaline deposition, °244

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84 | March-April, 85-166 | May-June, 167-252
July-August, 253-338 | September-October, 339-420 | November-December, 421-500

ARTERIOSCLEROSIS
arterial reconstruction, °407
and atheromatosis, differences, °75
and capillary wall thickening, 255, 256
cerebral, mortality, 150
and duration of disease, 345-346
electron microscopy, from dermal papilla, 257
glomerulosclerosis, °241
heart disease, incidence in Negro, 114-118
internal carotid artery, °244
maturity onset diabetes, °241, °244
peripheral, and nerve conduction velocity, 48, 50
serum cholesterol, 347
retinal, in classification of severity, 447

ARTERITIS, and coronary intramural lesions, °70

ARYLSULFONYLUREAS
See also specific substances
in maturity onset diabetes, °405

ASCITES
melituria, 261
after sulfonylurea therapy, 90-99

ASCORBIC ACID, and blood glucose, °400
artifactitious elevation, °494

ASPIRIN
fatal reactions, 109
hypoglycemic effects, °76, °401
side effects, °76

ASTHMA
bronchial, and diabetes, 455, 456
and overweight, 129

ATHEROSCLEROSIS
arteriolar involvement, °491
arteriosclerosis differences, °75
and cholesterol, 181, 189, 217
electron microscopy, °490
coronary, and eating habits, °326
and diet, °70, °244
in laying and nonlaying hens, °240
saturated fat, °330
lactose effect, 189
plaque, and metabolic disturbance, 396
reversibility, °243
sucrose effect, 189
thrombogenic theory, 396

ATROPHY
achlorhydria, and gastritis, °398
brain, autopsy findings, 98
and maturity onset, °241
pancreatic acinar, °161
sternocleidomastoids, 229
after sulfonylurea treatment, 90-99

ATROPINE, and blood flow in forearm and hand, °154

AZOTEMIA, and sulfonylureas, 97

B

BACTERIURIA, °162
asymptomatic, and pyelonephritis, 227
incidence, 231

BANTING MEMORIAL LECTURE, 409, 421-431

BARBITONE SODIUM, and hyperglycemia, °403

BASUTOLAND, diabetes surveys, 287-288

BEHAVIOR
and diabetes control, °239
in summer camp, °407
and pancreatic adenomas, °326

BELL'S PALSY, ophthalmoplegia, °402

BENEDICT'S TEST, 280-285

BERTRAM, Ferdinand, 324-325

BIGUANIDES
and carbohydrate metabolism, °326
gastrointestinal side effects, °76
hypoglycemic effect, °76
and insulin requirements, °77
patient selection, °76

BIRMINGHAM, England, incidence, age and sex specific, °327

BLACK RIVER, diabetes prevalence, 286-288

BLEEDING TENDENCY, in glycogen storage disease, °332

BLOOD
See also Blood sugar; Plasma; Serum
ABO groups, in diabetes inheritance, 175
amino nitrogen, °237
after hydrocortisone, °328
and phenethylbiguanide, 57
and tolbutamide, 56
ammonia, after alloxan, °158
-aqueous barrier, and glucose, 424
cell types, individual differences, 197
coagulation, in retinal disease treatment, °331
and weight loss, °70
composition, °244
in hypoglycemia and heart disease, 118
in infant and antepartum, 377-378
after third-degree burns, °325
venous, after morphine, °334
cord, glycoproteins and diabetic mothers, 375-380
dyscrasia, fatal reactions, 109
Eik-Nes, Nelson and Samuels test, °161
exercise effects, °239, 294
fingertip tests, 280-285
fructose levels, after fructose, °326
glutathione content, °491
and insulin, 7
assay, °154, °494
after leucine, °242
-like activity and ammonium, °154
shock therapy, °79
and transport, 7, °154
ketone bodies. *See* Ketone bodies
lactate content, °72
and hemorrhage, °398
in von Gierke's disease, °243
oxygenation, °398
and insulin antagonists, °239
pyruvate levels, °72
renal, by gravid uterus, and body position, 195
shunt system, °406
mechanisms of action, 421
and stabinol, °157
transfusion, 109
urea nitrogen, 2
in hyperparathyroidism and acromegaly, °489
in pregnancy, 195-196
and sulfonylurea therapy, 90-99
viscosity, 393-395
volume, °237
after adrenalectomy, °398
after dextrose, °71
D-xylose levels and insulin, °239

BLOOD FLOW. *See* Circulation

BLOOD PRESSURE
See also Hypertension
in acromegaly, °489
and arteriosclerotic heart disease, 114
and capillary wall thickening, 255-257
after dextrose, °71
and ergotamine, °330
and hydrocortisone, 2
in hyperparathyroidism, °489
after insulin, 2
and phenmetrazine, °328
and renal clearance in pregnancy, 193-194
and trimethaphan, °330
and weight, 133
reduction, 121, 344

BLOOD SUGAR, °72
See also specific conditions
and acetate uptake, 86
in Addison's disease, °494
after adrenalectomy, °398
antepartum and, of infant, 377-379
arteriovenous difference and phosphorylation, °493
and ascorbic acid, °494
and blood viscosity, 393
and body temperature, 294-296
and carbutamide, °76, °401
and casein hydrolysate by mouth, °72
in Chinese hamster, 13, 16, 19-20
and chlorothiazide, °74
and chlorpropamide, °155
and cortisone, 35, 66
and 2-deoxy-D-glucose, °241
after dextrose, °71, °238
dietary response, 186-188
after emotional distress, 22

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

and epinephrine, °157
and ether anesthesia, °158
and in eye chambers, after glucose injection, °329
fasting, °75, 89, 112, 216, 298, °489
in alloxan subdiabetes, 124-125
in ketonemia, 24-32
partially depancreatized, 212-213
postpartum, 438-443
in pregnancy, 441-443, °490
at seven months, 438
fetal, 119
and placental insulin transport, 390
after fluorohydrocortisone, 183, 185
and food intake, 369
and foot problems, °73
after fructose, °326
in fructosuria, 261, °492
genetic factors, 175-177
and glucagon, °76
in von Gierke's disease, °243
and glucose metabolism, 310, °494
after growth hormone, °75, °329
in hemorrhage, °237
and hydrochlorothiazide, °74
in hypoglycemia, °242, °402, °494
idiopathic, 341
after hypophysectomy, 298
and insulin. *See* Insulin
and islet-cells, 16, 312-315, 341
and leucine sensitivity, °72, °156, °242, 341
in children, °330
and liver, gluconeogenesis, 426
and longevity, °490
in maturity onset diabetes, °405
and muscle work, 294, 425, 426
duration, 291-292
in newborn, 378
and maternal pretreatment, °238
in nondiabetic volunteers, 353-356
and overweight, 129, 366
after pancreatectomy, °158
and pancreatic adenomas, °326, 341
after phenformin, 20, 276, 277, °334
after phlorhizin, 185
and plasma fatty acids, 22-32, 89
posthypoglycemic encephalopathy, °158
postprandial, °159, 276, 287, °332
in prediabetes, 438-444
in pregnancy, 438-444, °490
and prematurity, 315, 319
and renal blood flow, °71
and salicylate, °402
after sorbitol, 221, 222
and sympathetic blockade, °330
and teaching, in basic science departments, 469
tests, 34, °73
Folin-Wu method, 60, 61, 66, °332
Glover-Edwards' kit, 280-285
glucose oxidase-catalase enzyme system, °494
screening, 100-104, °332, 357
Somogyi, °332
Nelson modification, 23, 66, 123-129, 280-285, 292, 312
ultra micro technic, 60
urine tests compared, 280-285
and tolbutamide, 20, °74, °155, 212-213, 216, 312-315, °334, °490
after tolcyclamide, °331
and urinary tract infection, 2
and urinary volume, °71
D-xylose effect, °239

BLOOD VESSELS
See also specific sites
arterial reconstruction, °407
arteriole wall thickening, °244, 254
capillary, °78, 195
and basement membrane, 167-174
skin, light- and electronmicroscopic study, 253-259
complications, °75, 210, 253-259, °407, °493
and diet, 210
and employment, °241
malignant, °328
microangiopathy, °79, °406
-aneurysms and retinopathy, 167-174, 195, °238, 393-395, °400, 452-454
and overweight, 150
renal lesions, 452-454
and serum cholesterol levels, °244
tunica mucosae lesions, °398
vas deferens calcification, °155
elastic membranes, 206, 210
glucagon-induced changes, °78
hypothalamic stimulation effect, 217
and insulin inactivation, 1
occlusive disease, 210
and body fat, °70
peripheral arterial disease, °491
resistance, after dextrose, °71
in severity classification, 447

BODY
fat deposition, °72
and eating habits, °326
See also Obesity, Weight
fluids, translocation and position, 195
growth, 210
in galactosemia, °400
in glycogen storage disease, °332
and growth hormone, °74
after L-leucine, °333
and vascular elastic membranes, 206
height and weight, in dosage, 353
individual differences, 197
temperature, and blood sugar, 294-296
muscle work effect, 294-296
weight. *See* Obesity; Weight

BONE
biochemical individuality, 197
marrow, and insulin-fluorescein, °79
and sulfonylurea, 96
in offspring of diabetic hamster, 16
and soft-tissue necrosis in ischemic foot, °242, °405

BOOK REVIEWS
Annual Review of Biochemistry, edited by J. Murray Luck, 68
Chemistry of Heredity, by Stephen Zamenhof, 69
Chemistry of Lipids in Health and Disease, by H. K. King, 69
Clinical Endocrinology, I, edited by Edwin B. Astwood, 152
Clinical Syndrome of Diabetes Mellitus, by John Lister, 152-153
Coma Diabeticum, by Rudolf Baumann, 486
Der Diabetes Mellitus als Volkskrankheit und Seine Beziehung zur Ernahrung, by Ernst-Günther Schenck and C. H. Mellinghoff, 235
Diabetes (with a Chapter on Hypoglycemia), by 54 authors; edited by Robert H. Williams, 68
Diabetes Mellitus: A Handbook for Nurses, by Marguerite M. Martin, 397
Diabetic Care in Pictures, by H. Rosenthal and J. Rosenthal, 153
Diabetic Manual, by Elliott P. Joslin, 68-69
Famous Faces in Diabetes, compiled by Cecil Striker, 486
Home Guide for the Diabetic. Diet Instructions, Recipes and Other Guidance, 153
How to Live with Diabetes, by Henry Dolger and Bernard Seeman, 69
Insulin, British Medical Bulletin, published by Medical Department, British Council, 235
International Biguanide-Symposium (Internationales Biguanid-Symposium) Proceedings of Conference held May 12-13, 1960, at Aachen, Germany, edited by F. Bertram and G. Michael, 234
Mechanism of Action of Insulin, edited by F. G. Young, 153
Metal-Binding in Medicine, edited by Marvin J. Seven, 322-323
An Outline of Chemical Genetics, by Bernard S. Strauss, 397
Practical Clinical Management of Electrolyte Disorders, by William J. Grace, 234-235
Principles of Human Genetics, by Curt Stern, 323
Publications by Dr. Hans-Walther Larsen: 1. Diabetic Retinopathy. 2. Atlas of Diabetic Retinopathy. 3. X-ray Therapy in Proliferative Diabetic Retinopathy, 323

BRAIN
blood vessel disease rise, 150
fructose utilization, 219
function and blood sugar, 426
glucose transfer rates, 425
hypoglycemic effects, °75
and amino acid levels after drugs, °400

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

mucormycosis, °334
neuron distribution, 197
sulfonylurea effects, 98
weight in infants, and maternal diabetes, °156, °238

BRITISH DIABETES SURVEYS, 287-288

BRONCHITIS, and overweight, 129

BRONCHOPNEUMONIA, and capillary wall thickening, 255

BURNS
chorioretinal, for retinal detachment, °311
and prediabetes, °76
and pseudodiabetes, °325

BUTYLAMINOBENZENESULFONYLUREA. *See* Carbutamide

1-BUTYL-3-P-TOLYLSULFONYLUREA. *See* Tolbutamide

BZ-55. *See* Carbutamide

C

CAFFEINE RESPONSE, 197

CALCIUM
absorption, in hyperparathyroidism and acromegaly, °489
and basal glucose uptake, °398
blood content in hypoglycemia and heart disease, 118
pelvic artery calcification, °155
serum content, in hyperkalemic paralysis, 456
vas deferens calcification, °155

CAMP NYDA, alumni employment, 476-481

CANCER, °328
and biochemical individuality, 197
hyperglycemic response, °158
and hyperinsulinism, °77
hypoglycemic syndrome, °159
pancreas, °74, °399
islet-cell, °78, °494

CARBOHYDRATE
assimilation, in pituitary gland, °240
dietary intake, 277, 432
and blood lipid levels, °73
and cardiovascular system, 189
and cholesterol levels, 174, 189
and division of meals, 152
and glucose tolerance, °161
and ketone bodies, 27-29, 277
and plasma free fatty acids, 27-30
source effects, 174, 189
in steroid diabetes, 186
and tolbutamide response, °492
tropical pattern, 209
for idiopathic infantile hypoglycemia, °72
and insulin, °240
enzymatic mechanism, 421
reaction, 152
requirement, 86, °240
metabolism, °71, °399
after adrenalectomy, °155
in atherosclerosis, 396
and 2-deoxy-D-glucose, °241
of epididymal fat pad, °400
and epinephrine, °155
genetic factors, 41, 260-268
See also Heredity
after glucagon, °71
and glucuronic acid production, °244
and growth hormone, °74
hepatic, 29, °399
and hydrochlorothiazide, °74
and lactic acid levels, °398
Nembutal, °155
in newborn infant, °238
prediabetic stage, °75
in pregnancy, °157
and maternal dextrose treatment, °238
tolbutamide tolerance test, °403
and working muscles, 289-297
placental transfer, °157
postprandial urine test, °332
stores, in neonatal pulmonary syndrome, °242
synthesis, °494
tolerance, and age, 44, °71
in aldosteronism, °494
mild diabetes, 66
prednisone test, °70
in relatives of diabetic, 64

CARBON DIOXIDE
graphic visualization, °76
production, in adipose tissue, °328
after insulin, °74

CARBUTAMIDE, 90
See also Sulfonylureas
glomerular elimination, °75
hypoglycemic action, and age, °76, °157
and pancreatic function in alloxan subdiabetes, 124-125
and renal function, °75
and thyroid function, °79
toxicity, °79

CARCINOMA. *See* Cancer

CARDIAZOLE, °79

CARDIOVASCULAR DISEASE. *See* Heart disease

CASE REPORT
adynamia episodica hereditaria, 455-459
anaphylactic shock, after insulin, 105-109
diabetes onset in middle age, °244
diabetic acidosis, 1
hypophyseal stalk section in insulin resistance, 110
jejunal mucosal pattern in diarrhea, 58
keloids formed at injection sites, 320-321
ocular myopathy and endocrine deficiency, 228
sulfonylurea-treated patients, 90-99

CATARACTS, °402
in galactosemia, 263
in juvenile diabetics, 476
melituria, 261

CATECHOLAMINES
free fatty acid response, °330
and morphine hyperglycemia, °334
urinary excretion, and 2-deoxy-D-glucose, °241

CHILD
See also Infant
blood lactate levels, in von Gierke's disease, °243
and camp programs, °79, 218-226, °407
cortisone-glucose tolerance test, 66
diabetic. *See* Diabetes, childhood
dietary intake, °407
sorbitol evaluation, 218-226
functional microangiopathy, °79
glucosuria, °407
growth and development, in galactosemia, °400
hypoglycemia, °407
after alcohol ingestion, °238
leucine-sensitivity, °330
pancreatic adenomas, °70, °326
psychological problems, °239, °407
renal clearance values, °79

CHLORIDE
intestinal absorption, °236
urinary excretion after desoxycorticosterone, 456

CHLOROTHIAZIDE, °74
in pregnancy, °159

CHLORPROPAMIDE
age factor, °157, °406
and long-term therapy, °407
and carbohydrate metabolism, °326
dosage, blood levels, and action relations, °398
hypoglycemic potencies, °155
in ketoacidosis-resistance, °244
mild diabetes, °407
and nerve conduction velocity, 48
and pancreatic function in alloxan subdiabetes, 124-125
phenformin combination, °236, °244, °398
serum concentration, °400
side reactions, °73, °77, °160
and thyroid function, °79
and tolbutamide, °73, °244, °398
toxicity, °160, °400

CHOLESTEROL
and anemia, °331
antepartum, 377
and of infant, 378
and atheromatosis, °490
hypothalamic stimulation effect, 181
in laying and nonlaying hens, °240
reversibility, °243

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

blood concentrations, after lipid mobilizer hormone, 177
and coronary disease, *73, 181
dietary control, *70, *73, 303
episodic hyperkalemic paralysis, 456
esters, and fatty acids, 86, 303
after safflower oil in juvenile diabetes, *494
and hyperlipemia, *240
intestinal absorption, 189
and linoleic ester, 288, 303
and liver, *162, 189, *327
acetyl co-enzyme A content, *71
metabolism and dietary fat, *327
and reticulocyte count, *331
serum content, *240, *243
after deoxyribonucleic acid, *332
and diet composition, *330
in free diet, *240
and duration of illness, 347
and eating habits, *326
after lactose, 189
after sucrose, 189
source effects, *155
on cardiovascular system, 174
synthesis, *162
acetate uptake, 86
species difference, *155
total, after fasting, *236

CHRISTIANA, Jamaica, survey, 286-288

CIRCULATION, 197
and blood sugar levels, *71, *490, *492
in hands and forearm after atropine, *154
insulin effects, *72
liver, *72
and glucagon, *78, *492
renal, *79
after dextrose, *71
of thyroid gland after glucose, *490
viscosity, and retinopathy, 393

CIRRHOSIS
and diabetes onset, *74
in galactosemia, 263
and glucagon, *161
melituria, 261
nutritional, *161
and sulfonylurea therapy, 95

CITRATE
and blood insulin-like activity, *154
regional metabolism and glucagon, *492
serum levels, and insulin, *158

CLINITESTS
blood tests compared, 280-285
glycosuria and proteinuria, *241
after phenformin, 276

COMA
and blood protein-bound iodine, *79
and capillary wall thickening, 255
and emergency therapy, *160
and hyperthyroidism, *330
and insulin resistance, 2-4
in latent diabetes, 208, 209
lethal potentialities, 109
and longevity, *490
and sulfonylureas, 97-98, *332
and unconsciousness, *403

CONGENITAL ANOMALIES, and diabetic pregnancy, 16, *156, *159, *238

CONVULSIONS
after alcohol ingestion, *238
and pancreatic adenomas, *326
and sulfonylureas, 97-98

CORONARY ARTERY
atherogenic effects, *70, 217
and cholesterol, *73, 347
of free diet, *240
and blood lipids, *73
and cholesterol intake, *73
hypothalamic stimulation, 181
and hypoglycemia, 118
in middle age onset, and longevity, *244
occlusion and capillary wall thickening, 255, 256

CORTISOL. *See* Hydrocortisone

CORTISONE
and blood sugar, 35, 66
and carbohydrate tolerance, 41, 65, 66
diabetogenicity, 182
and epididymal carbohydrate metabolism, *400
-glucose tolerance test, 33-40, *71, 351-366
and age, 64-65, 270, 361-364
and diabetic family history, 41
dosage effect, 66
genetic susceptibility, 64-65
in latent diabetes, 208-209
in prediabetes, 35-41, 351
in pregnancy, 35-40, 66
steroid diabetes, *76
in Weil's disease, 208-209
and heart glucose uptake, *492
for idiopathic infantile hypoglycemia, *72
and insulin resistance, 112
and hypophyseal stalk section, 111
and lipemic serum clearance, 177
in protein malnutrition, *161
and pyruvate gluconeogenesis in kidney, *159

CUSHING'S SYNDROME, and carbohydrate abnormality, *494

1-CYCLOHEXYL-3P-TOLYLSULFONYLUREA. *See* Tolcyclamide

D

D-860. *See* Tolbutamide

DBI. *See* Phenethylbiguanide

DESOXYCORTICOSTERONE and urinary volume, in hyperkalemic paralysis, 456

DESOXYRIBONUCLEIC ACID, *332
and islet cells, 470-475

DEXTRAN, and diabetes duration, 347

DEXTRO-AMPHETAMINE, in episodic hyperkalemic paralysis, 458

DEXTROSE, *72, *154

DIABETES MELLITUS
See also specific conditions; specific hypoglycemic agents
and acromegaly, *74, *159, 162, *489
and Addison's disease, *494
adynamia episodica hereditaria, 455
age of onset, *154, 269, *327, *331, *407, 476
and age of parent at onset, 272-273
and capillary wall thickening, 255
and genetic factors, 41, 175, 272
insulin lipodystrophy, coconut oil therapy, *157
and longevity, 149
and severity of disease, *244, 447
See also Diabetes, childhood; juvenile; maturity onset
alloxan-induced, *71
appetite adaptation, *73
and blood ammonia content, *158
free diet, *240
fructose metabolism, *328
and glucose, *159, *328, *405, *493
blood-aqueous barrier transport, *329
glycogen in uterus, *333
and infection resistance, 231
insulin assay after hypophysectomy, 300-302
ketoacidosis, *333
and kidney, *159, *328
livers, acetyl co-enzyme A content, *71
glucokinase activity, *326
glutathione content, *491
mannose metabolism, *328
and pyruvate, *159, *328
retinal changes, *404
flat retina technic, *158
serum cholesterol and free diet, *240
in snake, *158
species difference, 187
subdiabetic, 122-129
remission, 125
and atherogenesis, *70, *240, 345-346
See also Atherosclerosis
and atrophic gastritis, *398
and blood sugar. *See* Blood sugar
brittle, *236, *402
and employment, *241
and muscular activity-carbohydrate regulation, 232
childhood, 66, *70, *326, *407, 478
and camp programs, *79, 218-226, *407
dietary intake, *407
sorbitol as adjunct to therapy, 225
emotional problem, *239, *407
growth, *244
hypercholesteremia, *70

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84 | March-April, 85-166 | May-June, 167-252
July-August, 253-338 | September-October, 339-420 | November-December, 421-500

socio-economic factors, *70
in Chinese hamster, in offspring and parents, 12-18
ciliary process, basement membrane, 167-174
classification, *328
coexisting neoplastic disease, *242
complications, 46, *70, 150-151, *155, *238, *241, 344, *402, *406, *493
See also specific conditions; specific sites
congenital, 17
Diabetes Week, 82
diagnosis, 33-40, 151, *157
blood tests and urine compared, 280-285
after carbohydrate intake, *161
fasting conditions, 284
postprandial blood, *159
screening tests, *332
in neuropsychiatric, 100-104
See also specific tests
and diarrhea, 58-59, 220, 223, 278, *401
duration, *154, *238, *244
and capillary wall thickening, 255
and employment, 476, 483-486
and heart disease, 114, 346-350
and heredity, 149-150
and insulin reactions, 151
and latency, 207-208
and lipoprotein patterns, 345-350
and nerve conduction, 50
and severity, 447, 483-486
emergencies, *160
employment, *241, 476-481, *489
and episodic paralysis, 458
etiology, 63, 269, *491
familial incidence, *70, *72
heredity, 175, 265, 270
Chinese hamsters, 12-21
to nutritional status, 269
obesity, 66, *241, 344, *401
and parity, *327
stress, *328
future, 148
and galactosemia, 265
gastric mucosa, *398
and glomerulonephritis, *238
exudative, *241
and hemochromatosis, *72
hyperlabile, *242
and hyperparathyroidism, *489
and hyperthyroidism, *330
hypopituitarism, *492
incidence, 66, 150
Basutoland, 287-288
Britain, 287-288
Ghana, 287-288
Indonesia, phycomycosis, *241
in Israel, *237
immigrants, *238
in Jamaica, 287-288
in Jewish population, 150, *237, *238
longevity effects, 150
and marriage, 150
Southern Rhodesia, 287-288
Trinidad, 287-288
United States of America, 287-288
in veterans, 100-104
juvenile, 275-279, *328, 432, *494
employment, 476-481
and fetal mortality, 449
glomerular filtration rate, *75
marital status, 478
and muscular activity, carbohydrate regulation, 232
and periodontal disease, *162
phenformin, *236, 321-322
sorbitol as adjunct to therapy, 225
stable, 275-279, 321-322
after tolcyclamide, *331
and Kimmelstiel-Wilson's disease remission, *328
labile, *244
latent, 207-210
and aldosteronism, *494
and cortisone, 64, 66
after remission, 209
life insurance, *490
malabsorption syndrome, 59
maturity-onset, *71, *241, *244, 275-279, *328, 344, *405
chlorpropamide, *73
growth hormone, *405
hyaline islets, *327
long-term treatment, *407
and plasma insulin concentration, *162, 340
and stabinol, *157
tolbutamide, *73
and weight loss, *74
mild, and cortisone-glucose tolerance, 66
mortality. *See* Mortality
in myocardial infarction, *404
necrobiosis lipoidica, *155, *237
nephrosis simultaneous, *493
nerve conduction velocity, 46-51
neurotrophic ulcers of foot, *159
nonclostridial gas infection, *162
ocular myopathy, 228-231
with ovarian insufficiency, 228-231
ortho-cresotinate, *76
pancreatogenic, 12, *158
cancer, *74, *406
papillary necrosis, *162
paternal, and birth weights, *403
patient education, 151, 479
peripheral arterial disease, *491
pernicious anemia, *398
and pheochromocytoma, 188, *399
and pituitary gland, *76, 110-113, 187, *401
podiatry, *73
prediabetes, 33-40, 63-66, *73, *75, 150, *327, *328, 351, 399, *404, 438-444
term definition, 33
predisposition, 65, *241
remission, *74, 207
unexplained, *492
renal lesions, glomerular and vascular, *399
and salicylate, *402
secondary, *328
senile, *75
severity, *241, 269, 432
classification, *328
spontaneous, in Chinese hamster, 12-21
stable, 31, 275-279
and metahexamide, *401
steroid, *76
after glucocorticoids, 38
islets protection, 182-189
surgery. *See* Surgery
teaching and training, 475
chief problems, 259
correlation clinics, 285
endocrine experiments, 451
group therapy, 444
and indigent patient, 311
laboratory work, 451
in basic science departments, 459, 469
and patient's self-education, 444
practicing physicians, 444
research focused, 475
treatment, *70, 121, *236, *237, *399, *406, 432, 475
and adrenocortical steroid therapy, *243
antihyperglycemic drugs, 92, *244
tolbutamide tolerance test, *403
See also specific substances
coexisting neoplastic disease, *242
combination therapy, *236, *237
dietary. *See* Diets
psychological, *239
in tropics, 209
and tuberculosis, 150
in twins, 149, 446
unconsciousness with, *329, *403
unstable, 31, *237, *333, *406

DIABETES WEEK, 82

DIABINESE. *See* Chlorpropamide

DIARRHEA
in galactosemia, 263
after metahexamide, *401
and neuropathy, 58
nocturnal, 59
after phenformin, 278
after sorbitol, 220, 223

DIBENAMINE
and free fatty acids, *330
and morphine hyperglycemia, *334

DIBENZYLINE, *330

DIET
adynamia episodica hereditaria, 455
and atherogenicity, *73, *240, *244, *330
and blood ketones, 27, 277
and blood sugar, 186
caloric intake, *236, 432
and glucagon levels, *405
and glucosuria, *407
and insulin requirement, 86
in tropics, 209
carbohydrate intake, *73, 432
and blood lipid levels, *73, *237

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84 March-April, 85-166 May-June, 167-252
July-August, 253-338 September-October, 339-420 November-December, 421-500

and fatty acids acetate uptake, 87
and glucose tolerance, 34, *161
hyperlipemic effect, 432-437
casein, 303
children in summer camp, *407
and cholesterol, *73, *240, 288, 303
coconut oil, 288, 303, *327
cod liver oil, 189
corn oil, 288, *327, 432
unsaturated, *70
cottonseed oil, 189, 288, *327
diabetes control, *70, *242, *333
in combination therapy, *160
and glycosuria, 186, 225
and insulin requirement, 86, 225
juvenile, 218, 432, *494
modification and relapse, 209
pituitary, 187
steroid, 184-187
and vascular lesions, 210
diabetogenicity, 187
and latency, *74, 208-209
division of meal, and insulin reaction, 152
fat intake, *73, 189, *240, 288, *327, 432-437
and linoleic ester, 303
prefeeding and lipid mobilizer hormone response, 177
restriction, 449
and retinopathy, *158, *404
and vascular elastic membranes, 206
free, *240
galactosemia, 263
and intelligence, 264
leucine, *72, *156
and appetite, *333
and nerve conduction velocity, 48
olive oil, 288
protein, 209, 432
in protein malnutrition and cortisone, *161
and safflower oil, *494
sardine oil, 288
Sippy, 174
sodium glycocholate, 303
sorbitol, 218, 225
soybean meal, 189, 303
sunflower seed oil, 288
tolbutamide response, *492
and weight control, 121
in Weil's disease, 208

DIETHYLPROPION, in obese, *401

DIGUANIDES. *See* specific substances

DIHYDROERGOTAMINE
glucagon response, *78
and morphine hyperglycemia, *334

2,9-DIMETHYL-1,10-PHENANTHROLINE HYDROCHLORIDE, 60-62

DINITROPHENOL
and acetate uptake, *78
and glucose metabolism in baker's yeast, *78
and pyruvate uptake, *403

2,4 DINITROPHENYLHYDRAZINE, in ketonemia, 23

DIPHENHYDRAMINE, for insulin sensitivity, 108

DIPHOSPHOPYRIDINE NUCLEOTIDE, in sorbitol metabolism, 218

DIURESIS
hydrochlorothiazide, *74
after third-degree burns, *325

E

EDEMA
in diabetes insipidus, 195
and emergency therapy, *160
melituria, 261
pulmonary, 109
and sulfonylurea therapy, 90-99
and renal functions, in pregnancy, 193-195

EIK-NES, NELSON AND SAMUELS method, *161

ELECTROLYTES
in episodic hyperkalemic paralysis, 456
excretion after desoxycorticosterone, 456
intestinal absorption, *236
in newborn infants, *242
in pregnancy, 39

ELECTRON MICROSCOPY
beta cells, after tolbutamide, 460-469
lipid physiology, *490
renal lesions, *399
skin capillaries of diabetics, 253-259

ELECTROPHORESIS
insulin, *77, *154
antibodies, *162
crystalline components, 147
fluorescent, 142-147
resistance, 2, 6, *79
serum patterns, 2, 6, *77, *79
spontaneous diabetes, hamsters, 18

EMBOLUS, pulmonary, *244, 255

EMOTIONAL FACTORS
in childhood, *239, *407
in episodic hyperkalemic paralysis, 458
and ketonemia, 22

EMPLOYMENT, *160, *489
and age, 477
and educational attainment, 477
juvenile diabetics, 476-481
rejection of application, 479
screening for, *72
and severity of disease, *240-*241
well-controlled diabetic teacher, 479

ENCEPHALOPATHY, posthypoglycemic, *75, *158

ENDOCRINE GLANDS
See also specific glands
deficiency, and myopathy, 228
individual differences, 197
in offspring of diabetic hamster, 16
pharmacology, *239, *242
size variation, 113
and sulfonylurea, 96

ENGLAND, diabetes survey, 286-288

ENZYME SYSTEM
in fructose metabolism, 219
genetic factors, 113
and glucose metabolism, *71, 218, 280-285, 423-424
in glycogen storage disease, *243
hexokinase metabolic pathway, 262
inborn errors, 260-268
individuality, 197
and insulin, 421-424
in liver, *71, 260
in sorbitol metabolism, 219

EPINEPHRINE
adrenalectomy effects on, *155
and carbohydrate metabolism, *157
and citrate metabolism, *493
and fatty acids, nonesterified, *492
and gas exchange, *74
and glucagon, *78
protein metabolism effects, *328
and glucose, *74, *155, 426
regional metabolism, *492
release from adipose tissue, *494
and glycogen deposition, *155, *494
and heart oxygen uptake, *491
and hyperglycemia, *158, *403
after hypoglycemia correction, *75
and insulin effects, 118, *494
and intestinal smooth muscle, *325
and lactate, *74, *493
and Nembutal effects on, *155
and pyruvate, *492

ERYTHEMA MULTIFORME, *160

ERYTHROCYTES
and cholesterol intake, *331
enzyme deficiencies, 260-268
in galactosemia, 262
in hereditary nonspherocytic hemolytic anemia, 266
and primiquine sensitivity, 265-266
in episodic hyperkalemic paralysis, 456
fluorescent insulin-sensitized sheep, 144
forearm blood flow, *71
and atropine, *154
fructose utilization, 261
galactose-1-phosphate, *243
uridyl transferase, 264
glucose-6-phosphate dehydrogenase deficiency in anemia, 265, 266
glucose transfer rates, 425
glutathione, 265
in glycogen storage disease, *243, *332
and insulin, 144-147
resistance, 2
in kidneys in hamster offspring, 16

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84 | March-April, 85-166 | May-June, 167-252
July-August, 253-338 | September-October, 339-420 | November-December, 421-500

transmetatarsal amputation for distal gangrene, °407
and necrobiosis lipoidica, °155, °237
nerve conduction velocity, 47
neuropathy, °242
and foot-drop, 49
peripheral arterial disease, °491
and podiatrists, °73
tufting of terminal phalanges, °489

ESTROGEN
metabolism, varying pattern, °75
in panhypopituitarism, °492
urinary excretion, diabetic pregnancy, °75
and uterine glycogen deposition, °333

ESTRUS CYCLES in Chinese hamster, 19

ETHANOLAMINE, and amino acid levels, °400

EXERCISE
and blood sugar, °239, 291-294, 425, 426
in hyperlabile, °242
and galactose distribution, 425
and glucose, 232, 296
arterial-venous differences, 293
humoral factor production, 289-303
hypoglycemic effect, 233, °239
and insulin, 152
metabolic effects, 289
local effect in working muscles, 295
and sugar transport, 425
and weight control, 121
d-xylose transport, 140

EXTON'S SULFOSALICYLIC ACID TEST, °241

EXTREMITIES
calcification of vessels, 257, 447
capillary changes, 253-259
foot lesions, °159, °242, °491
and blood sugar, °73
ischemic and neuropathic differentiation, °405
soft tissue necrosis, °405

EYES
See also Retinopathy
aging process, 173
of albinos, 197
aqueous humor, °329
in nephropathy, 173-174
ciliary processes, 167-174
complications, 150-151, °402
and emergency treatment, °160
in juvenile diabetics, 476
retinal microaneurysms, °494
fetal lens, and transplacental galactose transfer, 263
light-coagulation retinal detachment in treatment, °331
and ovarian insufficiency, 228-231
sheep, antiserum agglutination, °332

F

FALMOUTH, diabetes prevalence, 286-288

FAMILIAL TENDENCY, °72, 177, 208
age at onset, 149-150, 270
and beta cells potential reserves, °76
and carbohydrate metabolism, 41, 260
and cortisone, effects, 41, 351
galactosemia, 264-265
and glucose-6-phosphate dehydrogenase activity, 266
and glucose tolerance, 41, 63, °491
gout, °237
hemochromatosis, °72
in hypercholesteremia, °70
hypoglycemia, idiopathic, °156
periodic paralysis, 455
and prediabetes, 33, 36-38, °73
primaquine sensitivity, 266

FAT. *See* Lipids

FATTY ACIDS, 288
in adipose tissue, °404
release, °72, °494
deficiency, after coconut oil diet, 303
esterification, 436
free, 219-223, °241, °327, 432
and 2-deoxy-D-glucose, °241
and dibenamine, °330
and dibenzyline, °330
and ergotamine, °330
and epinephrine, °327
and fasting, °236, °327
and ganglionic blocking agents, °330
and glucagon concentration, °334
hypoglycemia, °407
in ketonemia, 22, 31
nutritional effects, 288
after pituitary thyrotropin, °239
plasma levels, 86, 233, °330, 432
after saturated fat, 318
and trimethaphan, °330
and fructose metabolism, 219, 220
and glucose, °327, °334, °494
oxidation in epididymal tissue, °404
glycerol uptake, °494
and insulin, °327, 436, °494
in hyperthyroidism, °328
after lipid mobilizer hormone, 177
nonesterified. *See* Fatty acids, free
serum levels, °236
and sorbitol, 219, 221, 223
synthesis, 436
from acetate, 85-89, °329
lipogenesis, °162

FECES
of albinos, 197
fat content, and dietary fat, °327
incontinence, and diabetic diarrhea, 58

FERDINAND BERTRAM, 324-325

FETUS, °327
anomalies, 448
and viable infant losses, 446
chorion, glucose uptake, °236
of diabetic Chinese hamster, 16
insulin, clearance after injection, 385
placental transfer to, °329, 383-392
lens damage and galactose-1-phosphate transplacental passage, 263
loss, °156, °238, 449-450
classification, 446
death in utero, 448
macrosomia, 16
miscarriage, 478
neonatal death, °238
and renal function, 191, 448
survival, °159
See also Pregnancy, management

FINGER-TIP BLOOD TEST, 280-285

FLUID
cerebrospinal, 197
extracellular, and glucose transport, 424
after hexose, °236
individual differences, 197
intestinal absorption, °236
intravenous, in diabetic coma, °330
lymphatic, hypoglycemic properties, °239
postural effects, 195-196
after sodium chloride, °236

FLUORESCEIN-INSULIN, °79, 142-147

9 α-FLUORHYDROCORTISONE, diabetogenicity, 182-188

FOLIN-WU TESTS, 60, 61, 66, 280-285, °332

FOODS
See also Diet; Nutrition
adaptation, °73
and growth in galactosemia, °400
habits, °405
and metabolic diseases, °326
in tropics, 208-209
ingestion amounts, depression, after glucagon, °405
after diabetes onset, 13
and hyperlipemia, 432-437

FRUCTOKINASE, 261-262

FRUCTOSE
and glucose, 220
uptake from blood stream, °326
insulin-like activity in normal men, °326
intestinal mucosa absorption, 220
and liver, °72, 219, 220
metabolism, °72, °160, 260-262, °492
in fructosuria, °160
inborn errors, 260
and kidney, 220, °328
pathways, 219
placental transfer, °157
rationale for use, 219
and sorbitol, °72, 218
structural formula, 218
urinary excretion, °160, 260, °492
in nonglucose meliturias, °491

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84 March-April, 85-166 May-June, 167-252
July-August, 253-338 September-October, 339-420 November-December, 421-500

FRUCTOSE 1, 6 DIPHOSPHATE, in metabolic pathways, 219, 262
FRUCTOSE-6-PHOSPHATE, 219
FUNGI, cerebral mucormycosis, °334
FWH 114. *See* Stabinol

G

GALACTOSE
absorption, and deoxy-D-glucose, °240
blood concentration, 263, 315, 426
in eviscerated-nephrectomized, 422
genetic mechanism, °240, 260, 265
mental and physical development, °400
resting and worked legs, 289-297
and blood sugar, in prematurity, 315
body distribution, 425
dietary restriction, and growth in galactosemia, °400
and epinephrine, 426
excretion in nonglucose meliturias, °491
in fructose metabolic pathway, 262
and glucose-1-phosphate, °243, 261
heart uptake, °491
hypoglycemia, 315, 319
and insulin, 423, 426, 428, °491
seasonal changes of efflux, °401
intestinal transport, °240
metabolism, in erythrocytes, 262
tolerance test, 315

GALACTOSE-1-PHOSPHATE
in erythrocytes, 261, °243
in fructose metabolic pathway, 262
and glucose oxidation by leukocytes, °161
transplacental passage, and fetal lens damage, 263
uridyl transferase, in galactosemic children, 261, 315

GALES CREEK CAMP, °79

GANGRENE
arterial reconstruction, °407
mortality, 150

GASTRIC SECRETION, and hypoglycemia, °79

GASTRITIS, atrophic, °398

GASTROINTESTINAL TRACT, 197
cellular infiltrates, 94
chloride absorption, °236
fluid transfer route, °489
fructose metabolism, 220
and galactose metabolism, 422
and glucose, °325, 425, °489
granulomata and sulfonylureas, 90-99
hemorrhage, and maturity onset, °244
hexose absorption, °236
microgranuloma, 94
and nocturnal diarrhea, 59
after phenformin, 276-277
sorbitol metabolism, 220, 224
sorbose absorption, °325
spindle-cell sarcoma, and hypoglycemia, °79
sugar transport, °240, 425, °489
and digitalis, °326

GASTROPARESIS DIABETICORUM, 59

GENES, 175-177
See also Familial tendency; Heredity
homozygosity, 19
individuality, 197
and infectious disease susceptibilities, 113

GHANA, diabetes survey, 287-288

GLOMERULI
and carbutamide, °75
hyaline changes, °238, °244
in pregnancy, 191
and edema, 196
and glucose tubular reabsorption, 195
postural effects, 195-196

GLOMERULONEPHRITIS, and duration of disease, °238

GLOMERULOSCLEROSIS, °244, °325
arteriosclerosis, °241
exudative lesion, °241
insulin requirement, °158
intercapillary, °79
association with aging, 17-18
Chinese hamsters, 18, 19
and renal function, 191
nodular, °158
and sulfonylurea therapy, 90-99

GLOVER-EDWARDS GLUCOSE TEST KIT, 280-285

GLUCAGON
adrenodemedullated rats, °78
antibodies, °494
in benign essential fructosuria, °492
and blood sugar, °78, 302, 341
after dextrose, °71
after tolbutamide, °71
and carbohydrate metabolism, °71
of epididymal fat pad, °400
and carbutamide effect, °401
and citrate metabolism, °492
duration of effect, °161
extrahepatic effects, °237
fasting effects, °328
in hypophysectomization, 302
and fatty acids, °76, °494
food intake depression, °405
and glucose, °76
heart uptake, °493
regional metabolism, °492
and hindquarter blood flow, °78
hyperglycemic response, °78
in infants, °238
and plasma 17-hydroxycorticoids, °161
in hyperinsulinism, °76
in hyperlipemia, °405
hypoglycemic treatment with, °237
immunoassay, °494
and insulin, °330, 341, 457
in fatty acid metabolism, °334
and lactate metabolism, °492
liver function test, °71, °237
in nitrogen metabolism, °76
in pancreatectomized snakes, °158
and protein metabolism, °328
and pyruvate, °492
and renal blood flow, °71
secretion, °237
zinc, dosage and liver glycogenesis, °161

GLUCOCORTICOIDS
and carbohydrate metabolism, °494
and glucose tolerance, 63
in pregnancy, 39

GLUCOSE
in adipose tissue, °77, °78
and amino acids, 428
after epinephrine, °74
release, °494
and adrenalectomy, phosphorylation effects, °493
arterial-venous differences, and exercise, 289-297
blood levels. *See* Blood sugar
brain level, °400
consumption, after alloxanization, °73
conversion to carbon dioxide, 53, °243
diabetogenicity, 187
and electrocardiograms, in hypoglycemia, 118
epinephrine effects, °74, 494
in eye chambers, °329
forearm uptake, °71
and free fatty acids, °241
and fructose, 219
in fructosuria, °492
and galactose absorption, °240
and glycogen in liver, °243
heart uptake, °406
and growth hormone, °492
hepatic output, 305, 306, 309, °399, 426
adrenocortical hormone therapy, °242
and tolbutamide, 52
for hypoglycemia correction, °75
and hypophysectomy, °492, °493
and insulin, 184, 304-311, 342, °398, °399, 428
Barnett-Ball theory, 427
direct effect on central nervous system, °243
Fisher's theory, 427
"free" and "bound" ratios, °488
intracellular transfer rate, °331
-like material assay, °77, °78
mechanisms of action, 421
and membrane flow rate, 427
phosphorlyation effects, °493
serum activity, °78
simultaneous administration, °72
transport theory of action, 424, 427
intestinal absorption, °325
in jejunal and ileal loops, °236
and kidneys, °328
filtration and reabsorption, °489
nephrons handling, °493

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84 | March-April, 85-166 | May-June, 167-252
July-August, 253-338 | September-October, 339-420 | November-December, 421-500

and lactate levels, °72
in von Gierke's disease, °243
and lipids, °236
mobilizer hormone response, 177
in maturity onset diabetes, °405
metabolism, °156, °327, °328, °494
anterior pituitary gland, °240
in baker's yeast, °78
and body temperature, 294
and 2:4 dinitrophenol, °78
glucagon effect, °492
by hexose monophosphate pathway, °493
kinetic analysis, °493
in leukocytes, and galactose-1-phosphate, °161
and muscle work, 290
after pituitary thyrotropin, °239
and salicylate, °78
in newborn infants, °242
and phlorhizin, 184
phosphorylation, °329, °331, °494
by hexokinase, 424
placental transfer, °157, 390, °490
and plasma 17-hydroxycorticoids, °161
reduction to sorbitol, 218
renal threshold for, in pregnancy, 195-196
storage, 426
and thyroid gland metabolism, °490
tolerance tests, °74, 287, °406
adrenocorticotropic hormone, 63, 351
and carbohydrate, °71, °161
and carcinoma of pancreas, °74
and cortisone, 33-40, 63-65, °74, °76, 208-209, 270, °327, 351-366, °404
criteria for interpretation, 64
and growth hormone, °75
in islet-cell adenoma, 341
in latent diabetes, 208
neuropsychiatric patients, 100-104
and overweight, 344, 366
and plasma insulin concentration, °162
and prediabetic, 33-40, °73, °75, °327, 351, °404
and cortisone, 63, 66
after prednisolone, 41-45
and prednisone, °70
in pregnancy, 35-40, 66, °327, 438
thirteen years after, °491
screening tests, 101-104
in severity classification, 447
in subtotal pancreatectomy, 211-217
after tolbutamide, 123, °404
transport, 304, °489
blood-aqueous barriers, °329
across cell membranes, °240, °331
sterospecificity of system, 425, 427
tubular reabsorption in pregnancy, 190, 194-196
uptake, 6, 130-133, °155, 203, °404
central nervous system, °243
and cyanide, °236
and dinitrophenol, °78
and epinephrine, °78, °492
gamma globulin fraction in insulin resistance, 6
and growth hormone, °492
in heart, °405, °493
and insulin, 6, 139, 198, °236, °237, 304
and l-leucine, °72
and muscle oxygen, 425
pancreatic tissue effect, °154
after phrenectomy, 139
after pituitary thyrotropin, °239
placenta, °236
and salicylate, °78
urinary excretion. *See* Glycosuria
utilization, 305
and hyperthermia, 294
and hypoglycemia, 306
and muscular work, 232

GLUCOSE-1-PHOSPHATE
in fructose metabolism, 219
and glycogen stores, °243
in sorbitol metabolism, 219

GLUCOSE-6-PHOSPHATASE, 267
in glycogen storage disease, °332
in liver tissue, °326
after carbutamide, °401

GLUCOSE-6-PHOSPHATE
after epinephrine, °494
fructose metabolism, 219, 262
and glucose utilization, 426
in sorbitol metabolism, 219

GLUCOSE-6-PHOSPHATE DEHYDROGENASE, genetic transmission, 260, 265

GLUCOSTAT ENZYMATIC REAGENT TEST, 432

GLUCURONIC ACID
placental transfer, °157
production and metabolic control, °244
urine excretion, in meliturias, °491

GLUTAMIC ACID, 53
and brain amino acid levels, °400

GLUTAMINE, °400

GLUTATHIONE, °400
and insulin, °491
-like material assay, °77, °78
after sulfonylureas, °491

GLYCERIC ACID, phosphorylation, 218-219

GLYCINE
and brain amino acid levels, °400
and liver protein uptake, °406

GLYCOGEN, °155
epididymal content, 291
in erythrocytes, °332
glycogen storage disease, °243
formation and breakdown pathway, 266
in fructose metabolism, 219
and insulin, 201-206, °327, 421
leukocyte content, °327
liver, °78
glucose uptake, 53
in hemorrhagic, °333, °399
precirrhotic, °489
and tolbutamide, °406
metabolism, in von Gierke's disease, °243
muscle, °333
exercised, 290-291, 295
in sorbitol metabolism, 219
storage, °78, 266-267
amylo-1, 4-1, 6-transglucosidase deficiency, °243
and carbohydrate metabolism, inborn errors, 260
endocardial fibro-elastosis, °162
and glucose-1-phosphate, °243
and glucose transport, 428
infant, °332
synthesis, °243, 266-267
transferase, 267

GLYCOSURIA
blood ketone, and plasma free fatty acids, 27
and carbutamide, °75
children in summer camp, °407
in diabetes survey, 287
diabetic hamsters, 19
Exton sulfosalicylic acid test, °241
after 9α-fluorohydrocortisone, 182-188
after glucose, 438-443
tolerance, 101-104
and hyperinsulinism, °402
in juvenile diabetes, 433-436
and longevity, °490
and overweight, 129
postpartum, 438-443
postprandial, 287
of pregnancy, 195-196, 438-443
renal, °76, 195-196, 260
response to diet, 186-188, 433-436
after sorbitol, 222-226
after third-degree burns, °325

GONADECTOMY, liver oxidation, °329

GONADOTROPIN
chorionic, and insulinase activity, °76
pituitary, 456
urinary, 456
in panhypopituitarism, °492

GOUT, in diabetes, °237

GRAVES' DISEASE, and thyroid medication, °330

GROWTH HORMONE, °74
adipose tissue, fatty acid release, °404
and body composition in newborn infants, °242
and carbohydrate metabolism of epididymal fat pad, °400
and fat mobilization, °71
and giant fetuses, 16
and heart glucose response, °492
human and bovine, and insulin effect, °400

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

hypoglycemic action after hypophysectomy, °329
and hypopituitarism, °74
in maturity onset diabetes, °405
obesity, °74
and sugar transport, 426, °492
and urine extracts, ketogenicity, °71

GUANIDINES, °326
See also specific substances

H

HAGEDORN-JENSEN METHOD, 438
modification, 34
HEART, 150
See also Myocardium
arrythmias, in hypoglycemia, 118
and carbohydrate, 260
source effects, 174
after dextrose, °71
and glucose, transfer system, 425-426
uptake, °403, °405, °493
growth hormone effects, °492-°493
and hypophysectomy, °403, °493
infant, distress, °331
cardiomegaly, °156, °238
insulin response, °405, 426, °491, °493
lethal potentialities, 109
muscle, °493
in offspring of diabetic hamster, 16
output, and glucagon, °78
oxygen uptake of perfused, °491
and phenmetrazine, °328
and sulfonylurea therapy, 90-99

HEART DISEASE
arteriosclerotic, 48, 50, 115-117
capillary wall thickening, 255
classification, 115
racial incidence, 114
hypertensive, and nerve conduction velocity, 48, 50
and hypoglycemia, 118
and longevity, 133, °490
luetic, 115
and overweight, 121, 133

HEMOCHROMATOSIS
familial, °72
and insulin resistance, 2

HEMORRHAGE
adrenal, and encephalopathy, °75
and carbohydrate metabolism, °398
cerebral and capillary wall thickening, 255
gastrointestinal, and maturity onset, °244
rectal, after chlorpropamide, °160
retinal, microaneurysms, 452-454

HEPARIN
for diabetic retinopathy, °491
lipemia clearance, and fasting, °236
necrobiosis lipoidica, °155, °237

HEPATECTOMY, and carbohydrate metabolism, °398

HEPATITIS, and diabetes onset, °75

HEREDITY
See also Familial tendency
adynamic episodica, 455
of diabetes, 149, 269-274
in Chinese hamster, 12-21
multifactorial hypothesis, 175-177
recessive gene hypothesis, 175-177
episodic paralysis, 455
fructose intolerance, °160
galactosemia transmission, °240
glucose tolerance test, 149
and cortisone, 64-65
hydronephrosis, 16

HEWSON CLINITRON APPARATUS, 280-285

HEXOSES, °156
See also specific substances
intestinal absorption, °236
placental transfer, °157
protein-binding, 396
serum levels antepartum, and of infant, 379

HIGHFIELD, Southern Rhodesia, 287

HORMONES
See also specific substances
lipid mobilizing, 177
and vascular lesions, 206, 210

HOUSSAY PHENOMENON, °76

HYALINE MEMBRANE SYNDROME, °156, °238
and neonatal death, 448

HYALURONIDASE, and lipemia clearance, 177

HYDROCHLOROTHIAZIDE, hyperglycemic reaction, °74

HYDROCORTISONE
and blood pressure, 2
and carbohydrate tolerance, 66
diabetogenicity, 182, °242
and glucose, 351
heart uptake, °493
and insulin resistance, 2
and hypophyseal stalk section, 111
in necrobiosis lipoidica, °155, °237
in pancreatectomized snakes, °158
in panhypopituitarism, °492
and protein metabolism, °328

17-HYDROXYCORTICOSTEROIDS
hypoglycemia, °407
plasma levels, °161
in pregnancy, 67
urinary, in hyperkalemic paralysis, 456

HYPERCHOLESTEREMIA. *See* Cholesterol

HYPERGLYCEMIA
in burn stress pseudodiabetes, °325
after 9α-fluorohydrocortisone, 182-188
glucagon, °76, °238
and plasma 17-hydroxycorticoids, °161
after guinea pig anti-insulin serum, °332
after hypophysectomy in snake, °158
and infant, °238
newborn, °242
and islet cells, 16, 182-188
zinc, granulation and reactive, 367-374
and ketone bodies, 29-30
latent diabetic, °74
morphine, catecholamine release, °334
after pancreatectomy, °158
plasma insulin levels, 339-343
postprandial, in diabetes diagnosis, °159
pregnancy, 16, °242
and fetal survival, 450
rebound, °402
after tolbutamide, 466

HYPERINSULINISM
after hypoglycemic bouts, °402
and islet cells, °76
tumors, °77, °78

HYPERLIPEMIA
See also Lipids
in glycogen storage disease, °332
and insulin, 435
in laying and nonlaying hens, °240
after low-fat, high-carbohydrate diet, 432
and rice diets, 432

HYPERPARATHYROIDISM, °489

HYPERTENSION
and bacteriuria, °162
and capillary hyalinization, 254
and cardiovascular disease, °70
arteriosclerotic, 116-117
and phenmetrazine, °328
and emergency therapy, °160
and employment, °160
in myocardial infarction, °404
nerve conduction velocity, 48, 50
in nodular glomerulosclerosis, °158
in pheochromocytoma, °400
and pregnancy, °159, 446-450
and hypoglycemia in infants, °155
and viable infant losses, 448
in retinopathy, °400
and sulfonylurea therapy, 90-99
transitory, 447
weight reduction, 121

HYPERTHYROIDISM, °328
in ketoacidosis, °330

HYPOGLYCEMIA
See also Blood sugar; specific hypoglycemic agents
and arrhythmias, 118
after aspirin, °401
and blood ketone concentration, 29
and capillary wall thickening, 255
in children after alcohol ingestion, °238

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

and chlorpropamide, °400
and convulsions, °238
and encephalopathy, °75, °158
and extrapancreatic neoplasms, °493
and fat mobilization, °71
in fructosuria, 261
functional, °77
after galactose, 315, 319
in glycogen storage disease, °332
after growth hormone, °329
and heart disease, 118
in hemorrhagic shock, °333
in hereditary fructose intolerance, °160
and hexamethonium, °407
humoral nature, °239
of muscle work, 233
and hypokalemia, 118
and hypophysectomy, °329
idiopathic, °70, 341
infantile, °72, °75, °156
insulin, °236, 310, °329, 339-343, °402
antibodies, °74, °79
and blood flow in forearms, °154
Crystalline, 146-147
and emergency therapy, °160
fluorescein isothiocyanate conjugated, 146-147
and gastric secretion, °79
and glucose, 306
in insulin resistance, 4
Lente, °154
nocturnal, 30
and phentolamine, 118
and plasma 17-hydroxycorticoids, °161
and rebound hyperglycemia, °402
and tumors, °76, °242
without warning symptoms, 151
and ketogenic activity of urine extracts, °71
after leucine, °155, °241, °330, 341, °400
and liver carcinoma, °158
metastatic invasion, °494
newborn infants, °155, 450
premature, 319
after pancreatectomy, snakes, °158
and pancreatic adenomas, °326
and panhypopituitarism, °492
after phenethyldiguanide tablets and capsules, °331
after phenformin, °236
postprandial, °156
in pregnancy, °490
reaction incidence, °70, °236, °399
shock, in diabetic hamsters, 20
spontaneous, °70, °79, °159, °403
and sulfonylureas, °71, 97-98, °399
after tolbutamide, °161, 341, °490
duration, 312
for paralysis agitans, °334
in Parkinson's disease, °332
in portacaval shunt, °406
and urine protein, °161
in von Recklinghausen's disease, °403

HYPOGLYCIN A, °400

HYPOPHYSECTOMY
and blood sugar, °329, °494
after insulin doses, 300-302
and glucose, °329
transport, °403
uptake, °403, °492
and hypoglycemia, °329
and insulin sensitivity, °403
after pancreatectomy in snakes, °158
D-xylose intracellular distribution, °490

HYPOPITUITARISM, °492
and growth hormone, °74

HYPOTENSION, postural, 58, 59
and body fluids, 195-196

HYPOTHALAMUS, °401
-pituitary, in insulin resistance, 112
stimulation, and hyperlipemia, 217

I

IMMUNE RESPONSE, insulin, °74, °402
See also Antibodies
crystalline, 107, °398
zinc, 144-145
and fluorescein isothiocyanate, 142-147
and hypophyseal stalk section, 110-113
plasma assay, °156, °162, 339-344
and proteins, 147
from different animal sources, 106-107, °332

INDONESIA, °241

INDUSTRY. *See* Employment

INFANTS
blood sugar, 450, °490
endocardial fibro-elastosis, °162
galactose tolerance test, 315
glucagon responsiveness, °490
glucose tolerance test, 315
glycogen storage disease, °162
hypoglycemia, °155, 450
cerebral damage, °156
idiopathic, °72, °75, °156
leucine sensitive, °241
and maternal diabetes, °70, °156, °238, °490
and birth weight, 150, °242, 377, °403, 438-443, 448-449
cardiopulmonary symptoms, °331
and dextrose pretreatment, °238
lipoprotein patterns, 349
neonatal complications, °238, °239, 450
neurological symptoms, °331
transitional distress, °159, °331
mortality, °238, °242, 448-449
pancreatic adenomas, °70, °326
and paternal diabetes, °403
and prediabetic pregnancies, °156, °327
prematurity, 315
serum glycoproteins, 375-382
thrombosed renal arteries, 448
vascular elastic membranes, 206

INFECTION
and latent diabetes, 208
mortality, 150
nonclostridial gas, °162
peripheral, °491
resistance, 227
urinary tract, in pregnancy, 191, 195

INSULIN
action, 421-431
in acromegaly, °159, °162
direct effects, 428
on central nervous system, °243
interference sites, 1
-like activity, 130, 425
after fructose, °326
of growth hormone, species specific, °329
transfer, by cross-circulation, 425
"translocation" theory, 424
unitary concept, 428
and adipose tissue, °154, °327, °404
adynamia episodica hereditaria, 455
allergy and anaphylactic shock, 105-109
desensitization, 107-108
after anesthesia effects, °157
antigenicity of, °79
arteriovenous difference, umbilical, °329
assay technics, °74, °154, °156, °162, 198-200, 201-206, °237, 298-303, 339-344, °402
of like substances, °77, °78
beef, 143
in guinea pigs, 3
and human anti-beef antisera, °402
and biguanides in labile diabetes, °76
binding, ratio to "free," °488
clearance, °79
renal, 7-11, °157
coma, 4, °330
after cardiazole, °79
Crystalline, °79, 106-107, 143-147, 302, 304, 457-458
cysteine-inactivated, °79
deficiency, after anti-insulin serum, °398
and 2-deoxyglucose phosphorylation, °329
in diabetes control, 19-21, 87, 232, °242, °244, 340, 432
and acidosis, °74, °489
in combination therapy, °160, °399
discovery, 488
and employment, °241
and encephalopathy, °75
experimental prevention, 187
prolonged treatment, 367-374
steroid, 186-189
and diet, 87
hyperlipemic effect, 434
See also Diet
dosage, °402
and employment, 476
meal relation timing, °242
as metabolic index, 221
mixture of long-acting with Regular, 152

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

after sorbitol, 222-226
suicidal intent, °404
and epinephrine, 118
in episodic hyperkalemic paralysis, 458
erythrocyte sensitization, 144-147
and fatty acids, 86, °241, °334, °404
fetal calf, 119-121
fluorescein, °79, 142-147
in fructosuria, °492
and galactose, 422, 426
efflux rate in summer and in winter, °401
glass adsorption, °334
and glucagon, °330, °334, 341, °400
free, °399, 457
and glucose, °236, 305, 331, 341, 423, 428
Barnett-Ball theory, 427
blood-aqueous barrier transport, °329
after cortisone, °400
and exercise, °239, 290
Fisher's theory, 427
after hypophysectomy, °403
metal ion effects, °398
in portacaval shunt, °406
tissue uptake, 199, 203, °403, °404, °405, °406, °492, °493
paralyzed hemidiaphragm response, 140
transport, 239, 304, 427
after triiodothyronine, °400
and glycogen deposition, 203
and heart, °403, °405
oxygen uptake, °491
human anti-beef-pork antisera, °402
and hyperketonemia, 30
in hyperthyroidism, °328
acute, °330
hypoglycemia, 4, °74, °76, °79, 146-147, 151, °154, °160, °236, °242, 306, 310, °329, 339-343, °420
inhibitors, °239, 351
latent diabetic, °74
Lente, °154, °404, 449
Chvostek reflex after, 457
lethal potentialities, 109
and leucine, °156, °242, °330, °333, °400
lipodystrophy, coconut oil therapy, °157
and liver, °162, 428
blood flow, °72
glutathione content, °491
nitrogenous products, 55
muscle uptake, °72, °232
and nerve conduction velocity, 48
NPH, 3, 7, 19-21, 87, 112, 204, 449, 455
and pancreas, °154
islets, 341, 367-374
after 9α-fluorohydrocortisone, 182-189
release, 217, 466
venous content, °78
and phentolamine, 118
plasma levels, °156, °162, 339-344
oxygenation effects, °239
pork, °402
and portal veins, °78
injection, °162
in pregnancy, °159, °242
placental effects, °236, 383, 390-391
in monkey, °329
Protamine, 103, 320-321, °333, 367, 449, 469
reaction, 105-109
and dextrose, °154
keloids at injection sites, 320-321
and recovery, °154
and sorbitol, 224
and steroids, °76
without warning symptoms, 151, 152
Regular, 152, 469
and renal blood flow, 7-11, °71
requirement, °77, °159, 276, 484
and adrenocortical steroids, °73
and adrenocorticotrophic hormone, 5, °73
and carbohydrate tolerance, 435
and diet, 87, 432
and longevity, °490
and nephropathy, 7, °58, °403
and oral hypoglycemics, °72, °154, °159, °160, 217, 325, 466
See also specific substances
and peridontal disease, °162
postpartum, °159
and prednisolone, 5
and prednisone, 5
after sorbitol, 222-226
and urinary tract infection, 2
resistance, 1-6, °73, °74, °79
hypophyseal stalk section effect, 110-113
and ketoacidosis, 4
species-differences, 21
secretion, °154, 217, 341, 466
and cortisone, 66
sensitivity, 3, °158
and encephalopathy, °75
serum binding, 3
shock therapy, °79
Sakel form, °75
in snakes, after pancreatectomy, °158
and sugar transport, 424-426
after tissue injury, 425
and tolbutamide, 112, 217, 340, 342, °399, 406, 466
tolerance, 118
and pancreatic adenomas, °326
in panhypopituitarism, °492
Toronto, 204
in Weil's disease, 208
withdrawal, and ketosis, °333
and d-xylose, 134-141, °239

INSULINOMA infancy, °70

INTERNATIONAL DIABETES FEDERATION FOURTH CONGRESS, 80-82, 164, 250

IODIDES
in cerebral mucormycosis, °334
renal clearance, 7-11

IPTD. *See* p-Aminobenzene-sulfamido-isopropylthiodiazol

IRIDOPLEGIA, °402

IRON, 109
serum level, and insulin resistance, 2

ISOVALERIC ACID, and hypoglycemia, °242

ISRAEL, incidence, °237

J

JAMAICA, prevalence, 286-288

JAUNDICE, °160, °401
premature infant, and blood glucose, 319

K

KELOIDS, at injection sites, 320-321

KETOACIDOSIS
See also Acidosis, diabetic; Ketosis
and hyperthyroidism, °330
after hypoglycemia, °402
insulin resistance, 4
and kidney, fatty infiltration, °333
after leucine, °330
and phenformin, 276, 321-322
and tolbutamide, °244, °334
and renal function, 191
susceptibility, °244
and unconsciousness, °329

KETONE BODIES
See also Ketoacidosis; Ketonuria
blood levels, °71, 221, °237, °407, °494
fasting, 24-32
and fat mobilization, °71
and ketonuria, 23, 27, 28, 31
after sorbitol, 221
splanchnic, 31
and urine extracts, °71
in Chinese hamster, 13
and diet, 27, 277
after emotional distress, 22
after exercise, 289
and hemorrhage, °237
and hyperglycemia, 30
hypoglycemia, °407
and overweight, 29
and plasma free fatty acids, 22-32
postprandial, 31
in shock, °237
sympathetic blockage effect, °407
test sticks, 13

KETONURIA, °161
in adult unstable, 275-279
hypoglycemic, nocturnal, 30
in juvenile diabetes, 275-279
in ketonemia, 23, 27, 28, 31
after phenformin, 277, 321

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84 | March-April, 85-166 | May-June, 167-252
July-August, 253-338 | September-October, 339-420 | November-December, 421-500

KETOSIS, 22
and anaphylaxis, 105
and endocrine abnormality, °489
in glycogen storage disease, °332
and insulin, 5
resistance, 105, °399
and obesity, and fasting, 29
sulfonylureas drugs, °71, °399

17-KETOSTEROIDS
in hyperkalemic paralysis, 456
in pregnancy, 39

KIDNEY, °79
See also specific conditions
aging process, 173
complications, 90-99, 150, 255
and age, °244
necrosis papillae, °162
and overweight, 133
fatty infiltration, °333
fructose phosphorylation, 218, 220
function in pregnancy, 190, 194-196
and galactose metabolism, 422
and glucose, °489
after partial pancreatectomy, 212
transport, 425
hydrogen ion excretion, °399
and insulin, °71
clearance, 7-11
and longevity, °490
in offspring of hamster, 16
polycystic, 255
pyruvate metabolism and cortisone, °159
recurring microangiopathies, °79
and salicylate, °403
and sorbitol metabolism, 218-220
and sulfonylurea therapy, 90-99
tubules, 220, °489
and blood ammonia, °158

KIMMELSTIEL-WILSON SYNDROME, °325
capillary aneurysm, basement membrane, 170
nodular lesions, °399
remission, °328

KWASHIORKOR, and cortisone, °161

L

LACTIC ACID
and acetoacetate uptake, °326
in adipose tissue, °74
after anesthesia, and epinephrine, °157
blood levels, °72, °158, °243
and anoxia, °398
and carbohydrate metabolism, °398
and hemorrhage, °398
and 2-deoxy-D-glucose, °241
in fructose metabolic pathway, 219, 262
and insulin, °158
after phenformin, 279
regional metabolism, glucagon effect, °492
and sorbitol metabolism, 219

LAWRENCE TAVERN, incidence, 286-288

L-LEUCINE
and blood sugar, °72, 341
and growth retardation, °333
and hypoglycemia, °156, °242, °330, 341, °400
spontaneous, °241
and insulin release, °156, °330
islet-cell adenomata response, 341
isoleucine antagonism, °333
sensitivity, °72, °330, °400
tolerance test, °241, °330

LEUKOCYTES
galactose-1-phosphate accumulation, °161
glycogen content, °327
glycogen storage disease, °243
and insulin resistance, 2

LIFE INSURANCE, °489-°490

LINOLEIC ACID, and cholesterol levels, 288, 303

LIPIDS
atheromatosis, °73, °490
and hypothalamic stimulation, 181
in laying and nonlaying hens, °240
blood ketone concentration, 31
and coconut oil treatment, °157
and coronary disease, °73
dietary effect, °240, °327, 435
fecal excretion, °327
fish-oil fraction effect, 316-319
glucagon regulation, °405
and glucose transfer rates, 425
in hyperkalemic paralysis, 455, 458
and insulin, 421, 435
after exercise, 289
intestinal absorption by pinocytosis, °490
metabolism, °72, 84-89, °490, °493
and 2-deoxy-D-glucose, °241
and growth hormone, °74
hypoglycemia-induced changes, °407
mobilization, in shock, °237
in myocardial infarction, and probenecid, °156
necrobiosis lipoidica, °237
and heparin, °155
in newborn, °242
phenformin effects, °327
phospho-. *See* Phospholipids
and serum cholesterol levels, °244, °327
transport, °491

LIPOPROTEINS
and coronary disease, °73
and free diet, °240
plasma, and unsaturated fat, °404
in pregnancy, 345-350
safflower oil, °494

LIVER
acetyl Co-A content, °71
and blood ammonia, °158
blood flow, °72, °78, °492
cancer, and hypoglycemia, °158
carbutamide effects, 95, °401
and chlorpropamide, °407
cholesterol, °162, 189
oxidation, °329
cirrhosis, °74, °75, 95, °161, 261, 263, °406
congestion, and myocardial infarction, °74
epinephrine effects, °327, °329, °492
fatty, °75
and dietary fat, °327
ketoacidosis, °333
and middle age onset, °244
in protein malnutrition, °161
fructose metabolism pathways, 218-219
and galactose metabolism, 422
in galactosemia, 263
and glucagon, °78, °329, °492
action duration, °161
mobilization, °401
glucokinase assay, °326
and glucose, 52-53, °72, 103, 305, 306, °327, °399, °401, °404, °420, °426, °492
and glucose-1-phosphate, °243
glucose-6-phosphatase activity, °401
glutamic acid, and salicylate, °403
glycogen, 53, °72, °161, °243, °329, °332
and blood loss, °339, °399
precirrhotic, °489
in shock, °237, °333
in hamster offspring, 16
hematopoiesis, 15
and insulin, 3, °72, °162, 305, 306, °327, 385, °399, 428
fluorescein clearance, °79
insulinase activity, 7, °75
ketogenesis, 22-32, 220
lactate uptake, °492
and l-leucine, °72
lipogenesis, °71, °155, °162
in melituria, 261
mesodermal tumors, °403
and mesoxalate, 52
and metabolism inborn errors, 260
metahexamide effects, °401
nonesterified fatty acid uptake, 31, °327
and overweights, 366
and phenethylbiguanide, 52
phosphorylase, °332
deficiency, 267
potassium contents, °489
protein metabolism, °329
pyruvate uptake, °492
and sorbitol metabolism, 218-219
and stabinol, °157
and sulfonamide preparations, °75
and sulfonylurea therapy, 90-99
and tolbutamide, 52-53, 56, 212, °403, °406, °491
transaminase output, 56
in von Gierke's disease, °243, 260, 267

LUTEOTROPIN, diabetogenic effect, 351

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

LYMPHATIC TISSUE
insulin-fluorescein clearance, °79
and insulin resistance, 2
in offspring of hamster, 16
and sulfonylurea treatment, 91-97

M

MALABSORPTION SYNDROME, 59

MALNUTRITION. *See* Nutrition

MANNOSE, °328
and intestinal galactose absorption, °240
and serum insulin activity, °78

MELITURIAS, 261, °402
nonglucose, °491

MENTAL HEALTH
retardation, 261
hypoglycemic infants, °155, °156, °158
and lactose-free diet, 264
in seventy-nine-year-old, °244

MEPYRAMINE MALEATE for insulin sensitivity, 108

MESOXALATE, liver response, 52, 56

METAHEXAMIDE, °244
and carbohydrate metabolism, °326
and thyroid function, °79
toxicity, °157, °401

METARAMINOL, and insulin resistance, 2

METHIONINE, in pregnancy, 195

MEVALONIC ACID, liver synthesis, °329

MORPHINE, 197
hyperglycemia, °334

MORTALITY
cardiovascular disease, 98, 121
arteriosclerotic, 114
drugs reactions, 109
and duration of illness, 149, 150
and islet hypertrophy, 209
hemorrhagic shock, °333
infant, °156, °238, °239, 446, 448-449
and life insurance practicability, °489
maternal, and diabetic pregnancy, 446
in myocardial infarction, °404
of overweight, 121, 133, 141
and blood sugar elevation, 129
perinatal, °72, 446, 448
and phenformin therapy, 277
and proteinuria, 178-181

MUCORMYCOSIS, °241
cerebral, °334

MUSCLE
acetoacetic acid uptake by, °326
blood flow after insulin, °72
carbohydrate metabolism, °155
epinephrine effects, °155, °325
fructose utilization, 219
galactose concentration, 292-293, 295
and glucose, °72, 290, 292
transfer, °331, 425-426
uptake, 233, °406, 423
and cyanide, °236
utilization, 292, 296
glycogen, 267, 291
and glucose-1-phosphate, °243
stores, °243, °332
humoral factor production, 289-297
individual differences, 197
and insulin, °72, 291, °331, 423, 426
and intracellular D-xylose, °490
myopathy with ovarian insufficiency, 228-231
pentose accumulation, °491
phosphorylase activity, °325, °332
in McArdle's disease, 267
and sugar transport, 426
work, 233, 290-296, 426
and blood sugar, 295
arteriovenous difference, 292
and body temperature, 294-295

MYOCARDITIS, and sulfonylurea therapy, 90-99

MYOCARDIUM
atherogenic effects, 117
of free diet, °240
decompensation infarction, °74
glycogen exposure and fibro-elastosis, °162
infarction, °404
and age, °244
carbohydrate source effects, 174
and hypoglycemia, 118
lipoprotein pattern, 347
recurrent, and coronary lesions, °70
and Sippy diet, 174
and sulfonylurea therapy, 90-99

N

NADISAN. *See* Carbutamide

NECROBIOSIS LIPOIDICA, °155, °237

NELSON-SOMOGYI METHOD, 66, 123-129, 208, 280-288, 292, 321

NEPHRECTOMY
See also Kidney
D-xylose intracellular distribution, °490
exercise, and sugar distribution, 425

NEPHROPATHY, °238, °325
See also Kidney
and capillary vessels, 255, 257
in classification of severity, 447
and diabetes remission, °328
and emergency therapy, °160
eye ciliary process, basement membrane, 167-174
and insulin requirement, °403
lipid mobilizer hormone, 177
and nerve conduction velocity, 48, 50
simultaneous diabetes onset, °493
and sulfonylurea therapy, 90-99

NERVOUS SYSTEM
in atherogenesis and hyperlipemia, 217
biochemical individuality, 197
and hypoglycemic symptoms, °77
insulin, direct effect, °243
phycomycosis, °241
stimulation with phenmetrazine and diethylpropion, °401
and sulfonylureas, 97

NEUROPATHY, °327
conduction velocities, 46-50
in myopathy, 229
infant transitional distress, °331
and insulin, 140, °157
and ischemia, °242, °405
and nocturnal diarrhea, 59
ophthalmoplegia, °402
and pancreatic adenomas, °326
peripheral involvement, 46, 50, 58, °491
posthypoglycemic encephalopathy, °158
and postural effects on body fluids, 195-196
in pregnancy, 195-196
and sexual impotency, 59
ulnar nerve involvement, 48

NEW YORK DIABETES ASSOCIATION SUMMER CAMP, employment-seeking experiences, 476-481

NEWPORT, incidence, 286-288

NITROGEN
amino acid, in shock, °237
fetal chorion, glucose uptake, °236
metabolism, °76
and phenethylbiguanide, 57
nonprotein, °326
and insulin requirement, °403
after third-degree burns, °325
and tolbutamide, 53
retention, after growth hormone, °74

NUTRITION, °161
and atrophic gastritis, °398
in diabetes, adult and juvenile, °402

O

OBESITY
and arteriosclerotic disease, 114-117
cortisone-glucose tolerance, 66
and diabetes manifestation, 150, °241
after amelioration, 207
and anorexigenics, °401
complication, 344
employment, °160
familial incidence, °70
genetic predisposition, 66
and glucose tolerance tests, 101-104, °491

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

and growth hormone, °74
and ketone bodies, 27-31
and longevity, 121, °490
and morbidity, 344, 366
and mortality, 133, 344, 366
and pancreatic adenomas, °326
and phenmetrazine, °328
in pregnancy, °491
and viable infant losses, 448
and tolbutamide tolerance, °403
weight reduction, 121, 344

OLEATE, and glucose oxidation, °239

ORINASE. *See* Tolbutamide

OVARY
hexose monophosphate shunt, °156
insufficiency, and ocular myopathy, 228-231
metastasizing dysgerminoma and hypoglycemia, °159

OXYGEN
consumption, °405
and heart perfusion, °491
after pituitary thyrotropin, °239
deprivation, °77, °405
carbohydrate metabolism during, °398
and microaneurysms, °238
and sugar transport, 425
and glucose, °405
intestinal absorption, °325
graphic visualization, °76
and insulin inhibitors, °239
saturation, and renal blood flow, °71

P

PALMITATE, and glucose oxidation, °239

PANCREAS
adenoma, °326
and encephalopathy, °75
after alloxanization, 124-125, 187
glucose uptake, °154
and blood ammonia, °158
and carbutamide, 124-125
and chlorpropamide, 124-125
glucagon, °330-°331
immunoassay, °494
and insulin, 124, °162, °330-°331, 340, 467
production, °72, 209
protection, 182-189
release, °154, 217
synthesis, 209
islets of Langerhans, adenomas, °70, 124-127, °162, °330-°331, 340
amyloidosis, °327
carcinoma, °74, °406, °494
and survival, °76
cell types
alpha, 13
classification, °157
removal and hyperlipemia, °405
and sulfonylurea therapy, 96
zinc content after insulin-treated, 373
alpha:beta ratios, 13, 14, °406
beta, 13, 16, 124-127, 183
and age, 39
and cortisone, °161
emiocytosis, 465
ergastoplasm, 462-465
glycogenization, 183-188
hydropic change, 183-188
and phlorhizin, 182-189
prediabetic degeneration, 17
spontaneous diabetes in hamster, 12, 16
in steroid diabetes, 183-188
after tolbutamide, 124-128, 211-217, 312-315, 460-469
zinc reaction, 368-373
and cortisone, 39, °161
growth patterns, 470-475
hyalinization, °241, °327
hyperplasia, 13, 16, 124-127, °156, 187
maternal diabetes, °238
hypertrophy, 124-127, 183-188
interdigitation with acinar tissue, 212
and latency, 209
lesions after fluorohydrocortisone, 183
maturity onset diabetes, °405
in medullary tumor, 188
and nodular glomerulosclerosis, °158
number, 16
in partially depancreatized, 212
postnatal growth, 472
and litter size, °160
proliferation, 17
regeneration, 125
regranulation, 465
secretions, °331
silver impregnation, °157
size, 16
species difference, 187
steroid diabetes, 182
and sulfonylurea therapy, 90-99
tumors, and hyperinsulinism, °76, °77
ultrastructural changes, 465
in latent diabetes, 208, 209
in maturity-onset diabetes, °241, °244
and p-aminobenzene-sulfamido-isopropyl-thiodiazol, 124-125
and p-aminobenzene-sulfamido-tertiobutyl-thiodiazol, 124-125
in protein malnutrition, and cortisone, °161

PANCREATECTOMY
and acetoacetic acid metabolism, °326
pancreatic adenomas, °70
partial, 211-217
diabetogenicity, 187
and glucose tolerance, 215
and tolbutamide, 211-217
during pregnancy, 16
serum insulin-like activity, in fasting state, °78
snakes, after hypophysectomy, °158

PANHYPOPITUITARISM, °492

PARA-AMINOBENZENE-SULFAMIDO-ISOPROPYL-THIODIAZOL, 124-125

PARA-AMINOHIPPURATE, clearance in pregnancy, 190, 192

PARALYSIS
familial periodic adynamia, 455-458
hyperkalemic episodic, 455-459
ophthalmoplegia, °402
after tolbutamide, in nondiabetes, °334

PARATHYROID GLANDS, hexose shunt, °156

PENICILLIN, 109
and periodontal disease, °162

PENTOBARBITONE SODIUM, °403

PENTOSES
See also specific
heart uptake, °491
insulin effects, 423-424, °491
intracellular transport, 423-424
in nonglucose meliturias, °491
placental transfer, °157
urinary excretion, °491
and carbohydrate metabolism, 260

PEPTIC ULCER
and diabetes employment, °160
after sulfonylurea therapy, 90-99

PERIODONTAL DISEASE, °162

PHENETHYLBIGUANIDE, 20, 277, °236, °242
See also specific substances
gastrointestinal side effects, °237
and insulin, 20, °70
requirements, 276, °399
and liver nitrogen, 52-56
and nerve conduction velocity, 48
resistance, species-differences, 21
tablets and timed-disintegration capsules, °331
and thyroid function, °79
and urea production, 56

PHENETHYLFORMAMIDINYLI-MINOUREA. *See* Phenformin

PHENFORMIN, 275-279
See also Phenethylbiguanide
and adrenocortical steroid therapy, °243
and age, °157
in brittle diabetes, °399
and carbohydrate metabolism, °326
in combination therapy, °160, 276
chlorpropamide, °236, °398
tolbutamide, °236, °244, °398, °399
in diabetic hamsters, 19-21
in hyperlabile, °242
and ketoacidosis, 321-322
resistance, °244, °334
in unstable, °237

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84 March-April, 85-166 May-June, 167-252
July-August, 253-338 September-October, 339-420 November-December, 421-500

PHENMETRAZINE
in cardiovascular disease, °328
in obese diabetics, °401

PHEOCHROMOCYTOMAS, °399
after epinephrine, °494
hypertension, °400
and islet cell degeneration, 188
microaneurysms, °400

PHLEBOTHROMBOSIS, °244

PHLORHIZIN, islet protection with from 9α-fluorohydrocortisone, 182-189

PHOSPHATASE, alkaline, after chlorpropamide, °77

PHOSPHATE
dihydroxyacetone, 218
in fructose metabolic pathway, 262

PHOSPHOETHANOLAMINE
and brain amino acid levels, °400

PHOSPHOLIPIDS
and acetate uptake, 86
and deoxyribonucleic acid, °332
and fasting, °236
high carbohydrate-low fat diet, 434
after lipid mobilizer hormone, 177
safflower oil in juvenile diabetes, °494

PHOSPHORUS
episodic hyperkalemic paralysis, 456
in hyperparathyroidism and acromegaly, °489
urinary, after glucagon, °328

PHRENIC NERVE, denervation, and d-xylose, 134-141

PITUITARY
ACTH reserve in panhypopituitarism, °492
extract, diabetogenicity, 187
glycogenesis, °240
hyperplasia, °159
hypophyseal stalk section, °401
in insulin resistance, 110-113
insufficiency, renal glycosuria coexistent, °76
and lipids, °240
mobilization, °72
and sugar transport, °156, 426
and sulfonylurea, 96
and thyrotropic hormone, °239

PLACENTA
carbohydrate transfer, °157
galactose-1-phosphate passage, 263
glucose uptake, °236
and insulin, °490
clearance, after injection, 385
transfer, °329, 383-392

PLASMA
amino acid responses, 289
cells, in microgranulomata after sulfonylurea, 91-92
chlorpropamide concentration and blood sugar, °155
cholesterol content, °155, 303
fatty acids, °330
free, 22-32, °76, °404
and 2-deoxy-D-glucose, °241
after glucagon, °76
and growth hormone, °76
after hypoglycemia, °407
and ketonemia, 22-32
and overweight, 29
postprandial, 31
after sorbitol, 222
fibrinolytic activity, 210, °489
glucagon effects, °76, °161, 341, °405
glucose clearance, 305, °494
in granulomatous nephritis, 97
hepatic flow, and ergotamine, °330
and trimethaphan, °330
17-hydroxycorticoids, 67, °161
and insulin, 7-11, °161, 289, 305, 385, °490
assay, °162, 298-299, 339-344
fetal, °329
and hypoglycemia after leucine, °156
and islet-cell adenoma, 341
protein fractions, °239
resistance, 2, 3-5
lipids, °405
and dietary intake, 317, 318, 432-436
fish-oil fraction effect, 316-319
synthesis from acetate, 84-89
lipoproteins, cholesterol-bearing, °404
phosphorus, in hyperparathyroidism and acromegaly, °489
renal flow, in lateral and supine position, 195
sorbitol levels and urinary loss, 221
specific gravity, and morphine administration, °334
trichloracetic acid precipitates, 7
umbilical arteriovenous difference, °329
water, and exercise, 289, 294
d-xylose content, °490
after phrenectomy, 140

PNEUMONIA
and capillary wall thickening, 256
and sulfonylurea therapy, 90-99

POTASSIUM
chloride, 118
Chvostek reflex after, 457
erythrocyte, episodic hyperkalemic paralysis, 456
and glucose uptake, °398
liver content, °489
metabolism, familial periodic paralysis, 455, 457

PREDIABETES, 33-40, °327, °328, 351, °404, °406
and blood sugar in pregnancy, 438-444
carbohydrate metabolism, °75
cortisone response, 63, 64, 66, 351
and exercise, 150
familial tendency, 33, 36-38, °73
and overweight, 150
prednisolone response, °73

PREDNISOLONE
and carbohydrate metabolism, °400
-glucose tolerance test, 41-45, 64, °73
in insulin resistance, 3
necrobiosis lipoidica, °155, °237

PREDNISONE
chlorpropamide toxic effects, °160
diabetogenicity, 182
-glucose tolerance, °70
and insulin requirement, 2, 4-5

PREGNANCY, diabetic, °72
See also Abortion, Fetus; Infant
acidosis, °159
blood galactose, and infant galactosemia, 263
blood sugar, in prediabetes, 438-444
complications, 447
fetal-pelvic disproportion, 449
microaneurysms, 195
delivery, °159
cesarean, 449
and vaginal, °238
timing of obstetrical intervention, °157
diabetogenic effect, 37, 39-40
and asymptomatic pregnancy, °493
onset during, 150
glucocorticoids during, 39
glucose tolerance test, °327, 441-443, °493
cortisone stressed, 35-50, 66, 67, 270
and prednisolone, °73
thirteen years after bearing large baby, °491
glycosuria, 441-443
in hamsters, 16-21
hyperemesis gravidarum, 191
hypertension and hypoglycemia infants, °155
and insulin, 21, °157, 391
placental transfer, °329, 383-392
requirements, °159, °492
juvenile diabetes, 478
and latent diabetic state, 207-208
lipoprotein patterns, 345-350
management, °72, °154, °238, °327, 441-443, 450
and body composition of newborn, °242
and chlorothiazide, °159
and tolbutamide, 21, °490
and transitional distress, °331
neonatal mortality, 449
overweight, 150
parity, °491
and diabetes incidence, °328
inheritance, 175
and perinatal mortality, °72, 445-451
polyhydramnios, 191
postpartum period, 349, 438, °490, °493
and prediabetes, 35-40, °76
preeclampsia, 446-450
in diabetes insipidus, 195

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

and prematurity, °155, °159, 315
prenatal care, °159, 449
renal function, 190-197
resorption, 19
risk classification, °154
severity of illness, 447
and transitional distress of infants, °160
and stillborn, 36, 349, 446, 449
toxemia, °159, 191, 193-194, 446-450
and hypoglycemic infants, °155-°156
urinary estrogen patterns, °75

PRIMAQUINE, sensitivity, 260
and glucose-6-phosphate dehydrogenase deficiency, 265-266

PROGESTERONE, in panhypopituitarism, °492

PROTEIN
and insulin, °154
requirement, 86, °239
intake, 432, °494
in free diet, °240
high, °404
in low-fat, high-carbohydrate diet, 432
in tropics, 209
malnutrition, and pancreatic dysfunction, °161
metabolism, °72, °494
after epinephrine, °329
and glucagon, °328
after hydrocortisone, °328
serum levels, 2, 6, 147, °406
antepartum and of infant, 378
glyco-, 375-382
stores, in neonatal pulmonary syndrome, °242

PROTEINURIA
in nodular glomerulosclerosis, °158
prognosis of diabetics with, 178-181
and renal clearances in pregnancy, 193-194
tests, °241

PYELONEPHRITIS, °399
and asymptomatic bacteriuria, 227
glomerulosclerosis coexistence, 195
insulin requirement, after prednisone, 2
lipomatosis, °244
in pregnancy, and renal function, 191-195

PYRUVATE
blood levels, °72
and brain, amino acid levels, °400
and epinephrine, °492
and ether anesthesia, °157
in fructose metabolic pathway, 219, 262
gluconeogenesis in kidney, °159
liver mitochondria oxidization, °329
metabolism, °159, °328
regional, and glucagon, °492
serum levels, °157-°158
and sorbitol metabolism, 219
uptake, °492
and salicylate, °403

R

RASTINON. *See* Tolbutamide

RESERPINE, 109

RETINOPATHY, °402
and capillary, °158, 173
function, and radioiodine clearance, °77-°78
wall thickening, 255, 257
and cholesterol levels, 347
eye ciliary process, basement membrane, 167-174
and functional microangiopathies, °79
heparin therapy, °491
humoral factor, °401
hypertension, °400
hypophyseal stalk section, °401
light coagulation in treatment, °331
microaneurysms, 167-174, °238, °400, 452-454, °494
and blood viscosity, 393-395
and nerve conduction, 43, 50
and pregnancy, 195, 448
and serum hexosamine, 393-395
in severity classification, 447

L-RHAMNOSE, intracellular transport, and insulin, 423-424

RICE DIETS, 432

S

SALICYLATES
and acetate uptake, °78
and adrenocortical steroid therapy, °243
blood sugar lowering effect, °402
and glucose metabolism in baker's yeast, °78
lethal potentialities, 109
and pyruvate uptake, °403
and serum transaminase activity, °403

SCHILLING TESTS, °398

SEROTONIN, release from adipose tissue, °494

SERUM
albumin, 110, 143-147, °325
in "true" insulin resistant, °77
alkaline phosphatase after chlorpropamide, °76
antibodies, 111-113, °325, °398
guinea pig insulin, °332
calcium, 456
in hyperparathyroidism and acromegaly, °489
chloride, after third-degree burns, °325
cholesterol contents, 189
and atherosclerosis reversibility, °243
after desoxyribonucleic acid, °332
and diabetes duration, 347
and diet, °155, 434
free, °240
and eating habits, °326
in juvenile diabetes, °494
and oral agents, °407
and sex of rat, °329
species difference, °155
and unsaturated fat, °404
citrate, °74
creatinine, in nephropathy, °403
electrolytes, °326
in episodic paralysis, 455, 456
fluorescence, fluorescein isothiocyanate, 143-147
glucose oxidase-catalase enzyme system, °494
in hereditary fructose intolerance, °160
hexosamine, 393-395
of horses, after cortisone, 177
insulin, °74
binding, 3, 5, °77, 209
bound-free ratios, 488
after hypophyseal stalk section, 111
idiopathic hypoglycemia, °156
-like activity, 3-6, 466
adipose tissue assay, 130-133
after fructose, °326
individual variations, 132
activity in maturity onset diabetes, °405
after prednisone, 3, 5
and pancreatic islet tumors, °78
and phenformin, °327
iron levels, 2
lipids, °240
and fasting, °236
in laying and nonlaying hens, °240
and safflower oil, °494
proteins, 2, 6, 147, °240, °406
glyco-, 375-382
and spontaneous diabetes in hamsters, 18
after tolbutamide, °406, 466
transaminase activity and salicylate, °403
uric acid, °237
and probenecid, °156

SHAFFER AND HARTMAN METHOD, °326

SHEEHAN'S SYNDROME, °76

SHOCK
anaphylactic, after insulin, 105-109
blood ketones, °237
glomerulosclerosis, exudative, °241
hemorrhagic, °398
irreversible, °333
hypoglycemic, °76
in diabetic hamsters, 20
insulin, and unconsciousness, °403

SIPPY DIET, 174

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

SKIN
of albinos, 197
capillaries, light- and electron-microscopic study, 253-259
in necrobiosis lipoidica, °155, °237
reactive pruritis, 321, °332, °401
xanthomas, and atherosclerosis reversibility, °243

SODIUM
dietary intake, °73
in episodic paralysis, 456
and electrocardiograms, and hypoglycemia, 118
excretion, after desoxycorticosterone, 456
and glucose uptake, °398

SOMATOTROPIN, °158
and glucose tolerance values, 351

SOMOGYI TEST, °332
Nelson modification, 23, 66, 123-129, 280-285, 292, 312

SORBITOL
in diet, of diabetic children, 218-226
formula, 218
and hypoglycemic reaction, 152
and insulin, 152
dosage, 222
rationale for use, 219
side effects, 223

SORBOSE, intestinal absorption, °325

SOUTHERN RHODESIA, incidence, 287-288

SPLEEN, and sulfonylurea, 96

STABINOL, °157

STEROIDS
See also specific substances
adrenocortical, 39, 63, °494
in cerebral mucormycosis, °334
and hypoglycemia, °403
idiopathic, °156
and insulin resistance, °73
and newborn body composition, °242
diabetogenicity, °76
and prevention, 182-189
fatal reactions, 109
glucogenic, and carbohydrate tolerance, 44
for hypoglycemia correction, °75
for islet cell tumors, °77
liver metabolism, and glucagon, °161
phlorhizin effects, 182-189
tolbutamide tolerance after, °403

STILBESTROL, and toxemia of pregnancy, °159

STRESS, °328
and blood sugar, 22
in hyperketonemia, 30
and onset of diabetes, 269
surgical. *See* Surgery

SUCCINATE, and oxygen uptake, °491

SUCROSE
atherogenicity, 189
and blood lactate levels, °72
excretion, in melituria, °491

SUGAR. *See* Blood sugar; also specific substance

SUICIDE, °490
insulin dose, °404

SULFOBROMOPHTHALEIN, retention and insulin resistance, 2

SULFONAMIDES, 109
See also Sulfonylureas

SULFONYLUREAS, °326
in combination therapy, °160, °398
hepatic insulinase inactivation, °76
histopathologic lesions postmortem, 90-99
hypoglycemia, °71
incidence of successes, °399
and insulin, °154
requirement, °71, °325, °328
ketosis, °71
secondary failures, 211
selection of patients, °71, °76, °403, °406
in snake, pancreatectomized, °158

SULPHONILYLBUTYLCARBAMIDE. *See* Carbutamide

SURGERY
arterial reconstruction, °407
hypophyseal stalk section, °401
in insulin resistance, 110-113
islet cell tumors, °77
carcinoma, °494
neurotrophic ulcers of foot, °159
and prediabetes, °76
tuberculous pulmonary disease, °404

T

2259RP. *See* p-Aminobenzene-sulfamido-tertio-butyl-thiodiazol

TEMPERATURE
body, 197
muscle work effects, 294
environmental, and blood sugar, 295
and glucose transfer, 424-425

TES-TAPE TESTS, 280-285

TESTOSTERONE, and insulinase, °76

THEVETIN, and glucose transport, °326

THROMBOANGIITIS OBLITERANS, °75

THROMBOCYTOPENIA, and insulin resistance, 2

THROMBOSIS
arterial and atheromatosis differences, °75
and capillary wall thickening, 255
and coronary artery intramural lesions, °70
etiology, 210
after sulfonylurea, 94
and weight loss and diabetes, °70

THYROID GLAND
carbutamide uptake, °79
metabolism, °156
and epinephrine, °490
and insulin, °162
and metahexamide, °79
methimidazole suppression, 7
in panhypopituitarism, °492
and tolbutamide tolerance, °403

THYROTROPIN
extrathyroidal action, °239
and glucose oxidation, °156, °490

THYROXINE, and insulin in adipose tissue, °328

TISSUE
adipose, 5, °74, °77, °78, °154, 423, 428, °488
and adrenocorticotropin, °404, °494
and amino acid, 428
epinephrine release, °494
free fatty acids release and blocking agents, °330
fructose utilization, 219
biochemical individuality, 197
carbohydrate stores, in newborn, °242
epididymal fat, °400, 405
and glucagon, °334
glycogen content, 291
exercise effects, 291, 294, 426
extracellular, sorbitol distribution, 221
and glucose, 130-133, °400, °404, °406, 423-424
transport, 425-426, 428
uptake, 140, 198-206, 421, °492, °493
glycogen deposition, 201, 202
growth hormone effects, °400, °404
and insulin, °328, °334, 423-428
assay, 138-140, 198-206
clearance, after injection, 385
complex, °154, °488
-like activity, 5, °77, °78, 130-133, °326
interdigitation, after tolbutamide, 216
after sulfonylurea therapy, 90-99
water content after phrenectomy, 138-140

TOLBUTAMIDE
and blood sugar, 20, °74, °155, °158, 212-213, 216, °244, 312-315, °334, °398, °490
and brain amino acid levels, °400
and carbohydrate metabolism, °326, °403
and ether anesthesia, °157
and chlorpropamide, °73, °76
in diabetic hamsters, 19-21
diabetogenicity, 187
diet effects on response, °404, °492

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84 March-April, 85-166 May-June, 167-252
July-August, 253-338 September-October, 339-420 November-December, 421-500

in fructosuria, °492
glomerular filtration rate, °75
and glucagon response, °71
and glucose, 54
in partial depancreatization, 211-217
glutathione response, °491
hypoglycemic effects, °73, °155, °161, °332, 341, °494
in portacaval shunt, °406
and insulin, 112, 217, 340, °399
plasma concentration after, 342
and ketone bodies, 27
and liver, °406, °491
nitrogen release, 52-57
pancreatic response, 95
in islets, 212-217, 312-315, 460-469, °494
adenomata, 341
in paralysis agitans, °334
in Parkinson's disease, °332
phenformin combination, °236, °334, °398
in ketoacidosis-resistance, °244, °334
and renal function, °75
resistance, °490
species-differences, 21
secondary failure, °76, 312-315
selection of patient, °157, °403, °406
long-term therapy, °407
serum phosphorus levels, °158
and thyroid function, °79
toxicity, 20, °73, 94, °332
urine excretion, °161

TOLCYCLAMIDE, °331

TRANSAMINASES, °78
glutamic oxalacetic, 56

TRIMETHAPHAN, °330

TRINIDAD, incidence, 286-288

TRIPHOSPHATE NUCLEOTIDE, and adrenal steroid production, °156

TRIPHOSPHOPYRIDINE NUCLEOTIDE
in primaquine sensitive erythrocytes, 266
in sorbitol metabolism, 218
xylitol dehydrogenase, liver deficiency, 260

TRYPTOPHAN, hypoglycemia, °330

TUBERCULOSIS
mortality, 150
surgical treatment, °404

U

ULCERATIONS
and necrobiosis lipoidica, °155, °237
neurotrophic, surgical correction, °159

UNITED STATES, diabetes survey, 286-288

UREMIA
and capillary wall thickening, 255
diabetic hamsters, 18, 19
and sulfonylureas, 97

URIC ACID
diabetogenic action, °237
serum, and probenecid, °156

URIDINE
and dinitrophenol, °78
and fructose metabolism, 231, 262, 267

URINE, 197
albumin excretion, 133, °160, °241, 261, 447, °490
amino acids, and screening test, °402
and autonomic neuropathy, 58
bacteria incidence, °162, 227
after manipulation, 231
flow in lateral and supine position, 195
fructose excretion, 260-261
in essential fructosuria, 160, °492
and heredity, 261
in nonglucose melituria, °491
graphic visualization, °76
in hyperkalemic paralysis, 456
incontinence, °326
ketoacids, °71
monocarboxylic, °330
in panhypopituitarism, °492
p-aminohippurate, 194
pepsin excretion, °398
phosphorus excretion, after glucagon, °328
polypeptide-like substance, fat mobilization, °71
porphyrin excretion, °332
radiolabeled insulin clearance, 7, 8
reducing substance, °491
in galactosemic family, 264-265
sorbitol excretion after ingestion, 221
and stabinol, °157
sugar content, °73, °162
and blood ketones, 28, 30
children, in camp, °407
diabetic hamsters, 13, 21
and eating habits, °326
after fluorohydrocortisone, 184
after hypoglycemic bouts, and hyperinsulinism, °402
as metabolic index, 221
nonglucose meliturias, °491
after phlorhizin, 184
and protein excretion, °161, °241
tests, 13, 28, 30, °332, °241
evaluations, 280-285
specific glucose oxidase method, °332
trichloracetic acid precipitates, 7
volume, 2
and renal blood flow, °71

V

VALINE, °333
hypoglycemic effect, °156

VASCULAR DISEASE. *See* Blood vessels

VITAMINS
absorption, after fructose and sorbitol, 220
nutrient needs, biochemical individuality, 197
supplementary multi-, 432

VON GIERKE'S DISEASE, glycogen in, °243, 267

VON RECKLINGHAUSEN'S DISEASE, °403

W

WATER
graphic visualization, °76
intestinal transfer, °489
intracellular, d-xylose distribution and insulin, 136-141
secretion, °242
in lateral and supine position, 195

WEIGHT
and diabetes control, °70, 207, 433-436
and fasting, °236
and food intake, 369
coconut oil, 303
soybean oil, 303
gain, 189
and glucose tolerance, 101-104, 344
loss, °74
and atherosclerosis reversibility, °244
fat metabolism, °70
and phenmetrazine, °328
and mortality statistics, 129, 133
and onset of diabetes, °74, 129, 150
inheritance, 175
latency, 208
of organs, gene interaction, 113
after phenformin, 276
and prediabetes, 150
and protein malnutrition, °161, °328
reduction, 207, 344
and anorexigenics, °401
specific benefits, 121, 141
after tolbutamide, in subtotal pancreatectomy, 211-212, 215

WEIL'S DISEASE, in latent diabetes, 208

WHIPPLE'S TRIAD, and pancreatic adenomas, °326

X

XANTHOMA, °243
dietary effect, and insulin, 435

XYLOSE
insulin response, 134-141, °239, °491
and muscle accumulation, 425, °490
and intestinal D-galactose absorption, °240
placental transfer, °157
uptake, 137-141
after phrenectomy, 138, 140

Z

ZINC
glucagon, and liver glycogenesis, °161
reactive, and islet cells, 143, 145, 367-374

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

AUTHOR INDEX 1961

In this index are the names of authors of articles that have appeared in DIABETES and those whose articles have been abstracted in the Journal during 1961. Entries marked with an asterisk (*) indicate authors of material that appeared in the ABSTRACTS only. For subject index see page 1.

A

Aagenaes, Ö., 253-259
Abbott, M. M., 119-121
Ackerman, R. F., 280-285
Alex, Morris, *70
Alfheim, A., *75
Allegretti, Niksa, *73
Allgood, J. William, 7-11
Allwood, M. J., *154
Alp, H., *401
Alterman, Seymour L., *70
Ammerman, C. B., *236
Anderson, Evelyn, 298-302
Anderson, Robert S., 114-118
Angervall, Lennart, *398
Annegers, John H., *236
Antoniades, Harry N., *154, *488
Appelman, David H., *325
Armin, J., *398
Arneaud, J. D., *157
Arney, Glen K., *325
Arquilla, Edward R., 142-147
Atkinson, William B., *333
Auerbach, Victor H., *155, *241, *242, *330, *400
Axelsson, J., *325

B

Baens, Gloria S., *238, *490
Bailey, Robert E., *331
Baker, R. David, *325
Baker, William H., 110-113
Baldwin, Robert S., *236
Ball, Eric G., *74
Ballard, Harold S., *334
Balodimos, Marios C., *154
Balter, Abraham M., 100-104
Baltz, Barbara E., *334
Barnard, Donald M., *154
Barron, Donald H., *236
Barry, Beryl A., *489
Barry, Frank M., *404
Barta, L., *70
Bass, Robert K., *162
Bassett, E. W., *325
Bates, Robert W., 298-302
Batson, Jack M., 105-109
Battaglia, Frederick C., *236
Beaser, Samuel B., *236, *398
Beatty, Clarissa H., *326
Becker, Bernard, 167-174
Becker, E. Lovell, *238
Beckett, A. Gordon, *70, *237
Beering, Steve C., *492
Beigelman, Paul M., 130-133, *237, *488
Beiser, S. M., *325
Bell, George O., *330
Bellet, Samuel, *156, *489
Benirschke, Kurt, *156, *238
Bergen, Stanley S., Jr., *237
Bergenstal, D. M., *76
Bergströmm, J., *489
Berman, Mones, *493
Berson, Solomon R., *162, 339-344
Bertrand, N. R., *70
Best, Charles H., 304-311, *330, 367-374, 482-483
Best, G. R., *329
Bhargava, S. P., *406
Bhattacharya, G., *398
Bierman, Edwin L., 432-437
Blahey, P. R., *75
Blair, Alberta, *493
Blaschke, John A., *77
Blechner, Jack, *236
Blood, Frank R., *327
Bloodworth, J. M. B., Jr., 90-99
Bloom, Arnold, *489
Bloom, Walter Lyon, *237, *398
Blumenthal, Herman T., *70
Bocek, Rose Mary, *326
Bogdonoff, Morton D., *241
Boley, Scott J., *70, *326
Bolinger, Robert E., *70, *399
Bookman, John J., 320-321
Bottomy, John R., *159
Bouman, P. R., *154, *155
Bounous, G., *71
Bowdler, A. J., *489
Bradley, Robert F., *330
Bradley, S. E., *489
Brandaleone, Harold, *489
Brandt, Lars, *399
Brandt, Ralph L., *71
Breithaupt, D. J., *489
Brennan, James C., *399
Bridwell, Travis, 58-59
Brod, Robert C., *399
Brown, Arnold L., Jr., *490
Brown, Josiah, *79
Brown, Mayo E., 60-62
Bryant, J. Marion, *328
Bueding, E., *325
Bühring, H., *71
Bülbring, Edith, *325
Buse, John, 134-141
Buse, Maria Gordon, 134-141
Butterfield, W. J. H., *71

C

Cadenas, E., *405
Cahill, George F., Jr., *328, *404
Caird, F. I., 178-181
Calandra, J. C., *73
Carter, Norman W., *244, *334
Castleman, Benjamin, *244
Cawley, Leo P., 455-459
Chaikoff, I. L., *162
Chalmers, T. M., *71
Chart, J. J., *239
Chernosky, Marvin E., *155, *237
Chesley, Leon C., *490
Clark, George C., *73
Clark, J. J., 289-297
Clark, Nigel, *162
Clarke, C. A., 175-177
Clarke, J. T., *402
Cline, D. W., *333
Cochrane, W. A., *72
Cogan, David G., 393-395, *402
Cohen, A. M., *237
Cohen, Richard J., *158
Cohen, Stanley N., 182-189
Cohn, Clarence, *326
Collado, Manuel, *400
Colombo, Jean-Pierre, 122-129
Conant, J., 351-366
Coniglio, John G., *327
Conn, Jerome W., 63-67
Cori, Carl F., *329, *331
Cornblath, Marvin, *155, *238, *243, *332, *490
Contreras, J. S., *401
Corvilain, J., *326
Court, Antonio L., 445-451
Cox, George E., *155, *243
Craig, James W., *155, *399, *404, *492
Csáky, T. Z., *326
Culver, Gordon J., *155
Cummins, Leo H., *238
Cunningham, N. F., *398
Curtis, George W., *156, *238

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

D

Dagenais, Yves M., °77, °78
D'Alonzo, C. A., °160
Dampeer, T. K., Jr., °72
Dancis, Joseph, °157
Danowski, T. S., °406
Daughaday, William H., °399
Davis, Joseph R., °326
Daysog, Alberto, Jr., °399
Demby, Allen M., °238
Dermer, W., °155
De Ropp, R. S., °400
Desjardins, Jay A., °399
Desmond, Murdina M., °159, °331
DiGeorge, Angelo M., °155, °241, °242, °330, °400
Dillingham, C. H., °72
Diment, Dean H., °77
DiPietro, David L., °326
Ditschuneit, H., °326, °400, °405
Dobson, Harold L., °399
Dodds, Sir Charles, °72
Domenge, Luis, 218-227
Donnell, George N., °400
Doray, Bernard H., °243
Dosekun, F. O., °72, °490
Dotevall, Gerhard, °398
Driscoll, Shirley G., °156, °238
Driskill, Helen J., 46-51, °406
Drucker, William R., °399
Dulin, W. E., 289-297
Duncan, Garfield G., °400
Duncan, L. J. P., °491
Dutton, Robert V., °159, °331

E

Eberly, Richard J., °400
Edelman, Jerry, °156
Egeli, E. S., °401
Ehrhardt, A., °333
Ehrlich, Joseph C., °327
Eichhorn, J., °490
Einhorn, Samuel, °160
Eisentraut, Anna M., °494
Ellenberg, Max, °327
Ellington, Anna, 114-118
Ellis, George S., °331
Elsom, Katharine O., °493
Elwyn, David H., °78
Emmons, Chester W., °241
Eng, Njo-Injo Tjoei, °241
Engel, Howard R., °76
Engelhardt, Hugo T., °72
Epstein, Stephen E., °238
Esmann, V., °327
Estes, E. Harvey, Jr., °241

F

Fajans, Stefan S., 63-67, 444
Feder, Isidore A., °401
Felts, John H., °403
Ferguson, Harold A., °327
Fernald, G. W., °326
Field, James B., °156, °239
Field, Richard A., 110-113, °401
Findor, J., °489
Fine, Melwyn B., °327
Fineberg, S. K., °73, °401
Finley, John K., °491
Fischer, Alfred E., °156, °239, °327
Fisher, Jean, °243, °332
Fisher, R. B., °401, °491
FitzGerald, M. G., °327, °491
Fletcher, Lucian, Jr., °328
Flinn, Robert B., °328
Foa, Piero P., 122-129
Folkart, Gladys R., °157
Fordham, Christopher C., °402
Forsham, Peter H., °74, °402, 475
Francis, John O. S., °161
Frank, Stanley T., °73
Frawley, Thomas F., °406
Freinkel, Norbert, °157, °239, °240, 383-392
Friedlander, Ernest O., °73
Fries, H., °79
Fry, I. Kelsey, °71
Futcher, Palmer H., 445-451

G

Gabric, Dora, °73
Gais, Elmer S., °491
Ganzon, Angelita F., °238, °490
Garber, Stanley, °407
Gardberg, Manuel, °239
Gardiner, D. C., °239
Gastineau, Clifford F., °242
Gaunt, Robert, °239
Gerszi, Kornel E., °78
Ghadmi, H., °402
Gilbert, J. A. L., °70
Gilgore, Sheldon G., °402
Ginsburg, Jean, °154
Givner, Isadore, °402
Glasser, Stanley R., °328
Godlowski, Z. Z., °73
Goetz, Frederick C., °157
Gofman, John W., °73
Gold, Solomon, °157
Goldberg, Harold H., °160
Goldberg, Lawrence G., °333
Goldberg, Richard I., 122-129
Goldenberg, Sidney, °70
Goldman, Jerrold, °160
Goldner, Martin G., °328
Goldstein, Jack E., °402
Goldstein, M. S., 232-234, °239
Goodman, H. M., °329
Goodner, Charles J., °157, °240, 383-392
Gordon, Harry H., °238, °490
Gordon, Mordecai H., °238, °490
Goto, Yoshio, 52-57, °73, 182-189
Graef, Irving, °328, 488
Grant, R. T., °398
Grayson, J., °72
Grebe, S. F., °79
Greene, Ruth, °79
Grisham, Joe W., 460-469
Grodsky, Gerold M., °74, °402
Gryglewski, R., °491
Gundersen, Kare, °154, °488
Gunter, Laurie M., 114-118

H

Hadley, W. B., 1-6
Hagen, August, 438-443
Hagen, Jean Himms, °74, °328
Haimovici, Henry, °491
Haining, R. B., °74
Haining, R. G., °74
Halikis, Demetreos N., 142-147
Hall, William A., 100-113, °401
Halprin, Harry, °74
Hamlin, James T., III, 432-437
Hamwi, George J., 46-51, 90-99, °157, °406
Hanauer, Lonnie, 105-109
Handelsman, Milton B., °402
Hannah, Ramsay, 275-279
Hare, Robert L., °79
Hargrove, Marion D., Jr., °74
Harlan, William R., °241
Harland, W. Arthur, °240
Harper, A. E., °333
Harper, Paul Vincent, Jr., °405
Hartmann, Alexis F., Sr., °402
Hartmann, H., °159
Hartzog, H. G., III, °326
Harwood, Reed, °74
Hasselblatt, A., °402
Hatch, Fred E., Jr., °328
Hausler, H. R., 452-454
Hawkes, Jean M., 280-285
Hayes, Donald M., °403
Healy, M. F., °157
Hechter, O., °490
Heller, Benjamin I., 259, 311
Heller, Irving H., °157
Hellerström, Claes, °157, °160, 470-475
Hellman, Bo, °157, °160, 470-475
Henderson, M. J., °403, °405, °492, °493
Henneman, Dorothy H., °74, °157, °492
Henneman, Philip H., °74
Hennes, Allen R., 85-89
Hennigar, Gordon R., °158
Herring, Betty, °156
Hess, Sigurd, °157
Hetenyi, G., Jr., 304-311
Hift, H., °333
Hill, R., °162
Hill, S. Richardson, °73
Hines, James J., °492
Hinkle, L. E., Jr., °405
Hobkirk, R., °75
Hodd, K. A., °404
Holland, Doris E., °241
Hollander, Richard J., °238, °490
Holowach, Jean, °402
House, Evelyn, °243, °332
Houssay, B. A., °158
Hsia, David Yi-Yung, °240, 260-267
Huggins, A. K., °403
Hugh-Jones, Kenneth, °240
Hultman, E., °489
Hümmer, N., °75
Hyman, Harris, °161

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

I

Iacono, J. M., °236
Isaac, G. J., °236
Ivy, A. C., °240
Izzo, Joseph L., °328

J

Jackson, W. P. U., 33-40
Janes, Ralph G., 312-315
Jenson, William, °400
Jessup, D. C., 198-200, 201-206
Johnson, Ernest W., 46-51
Johnson, Phyllis, °156, °239
Johnson, Roy B., °404
Jones, George M., °75, °158
Jorgensen, Charles R., °240
Joron, G. E., °75
Josimovich, J. B., °329
Joslin, Elliott P., 148-151

K

Kahn, Alvin, °401
Kalant, N., °240
Kalk, H., °75
Kalliomäki, J. L., °403
Kanameishi, Doris, 122-129
Kantrow, Abraham H., 476-481
Kaplan, Norman M., °403, °492
Kato, Joji, °73
Katz, Harvey P., °158
Kaufman, Mildred, °161
Kaufmann, Peter, °490
Kay, Jacob L., °159, °331
Kekwick, A., °71
Kellock, T. D., °403
Kendall, Charles, °70, °399
Kennan, Alfred L., °158
Kerkhof, Arthur C., °329, °403
Kershbaum, Alfred, °156
Kessler, Donald L., °492
Kim, Hae Sok, °154
Kinch, Kenneth E., °240
Kinsell, Laurance W., 316-319, °407
Kinsella, Thomas J., °404
Kinsey, V. E., °329
Kipnis, David M., °329
Kirshner, Norman, °241
Kirschner, Robert, °158, °404
Klein, Robert F., °241
Klimt, C. R., 351-366
Knights, Edwin M., Jr., °241
Knobil, E., °329
Knowles, Harvey C., Jr., 22-32
Koch, Richard, °400
Kohn, Kate H., °159
Korhonen, Jyrki, °404
Koskinen, Pentti, °404
Kraicer, J., 367-374
Krall, Leo P., °76
Kramer, David W., °75
Krecke, H. J., °158
Kritchevsky, David, °329
Kuhl, W. James, Jr., °161
Kühnau, J., °71

L

Lacy, Paul E., 460-469
Laibson, Peter R., 393-395
Lake, Anita J., °241
Lakin, Mervyn, °159, 228-231, °330
Lambert, R. C., 207-210
Lambert, Thomas H., °404
Landau, Bernard R., °159, °240, °404, °492
Laragh, J. H., °489
Laron, Z., °492
Laszlo, John, °241
Laufer, A., °241
Lawrence, R. D., 483-486
Lazarow, Arnold, 285, 451, 459, 469
Lazarus, Sydney S., °161, °241, °244
Leboeuf, Bernard, °328, °404
Leckie, R. B., °489
Lehmann, Klas-Erik, °398
Lehrnbecher, M., °75
Leibel, Bernard S., 119-121, 375-382
Leiter, Louis, °406
Leites, S. M., °75
Leonards, Jack R., °404, °492
Leopold, Irving H., °158, °404
Levin, Noah B., °159
Levine, Rachmiel, 421-431
Lewis, B., °404
Lewis, J. G., °237
Lewis, L. G., °70
Lie-Kian-Joe, °241
Lightbody, T. D., °76
Lin, Jane, °70, °326
Lindemann, Charles E., °404
Lindgren, Lars, °404
Linke, A., °158
Lipsett, M. B., °76
Lloyd, M. K., °398
Locke, Simeon, 228-231
Logothetopoulos, J., 367-374
Long, W. Newton, 445-451
Longfield, G. Maxwell, °241
Lowbeer, Leo, °493
Lowe, Charles U., °243
Ludwig, George D., °493
Lukens, F. D. W., 52-57, 182-189, °406
Luna del Villar, Jose, °331

M

Mabry, C. Charlton, °241, °242, °330, °400
MacDowell, Muriel, °489, °493
MacHattie, Lorne A., °76
Madison, Leonard L., °244, °334, °494
Mahan, Major Charles J., °162
Malins, J. M., °327, °491
Marble, Alexander, 218-227, 320-321
Marcó, Alicia, °326
Margulies, Edward J., °406
Markkanen, T. K., °403
Marks, Henry E., 487-488
Marks, Herbert H., 344, 366
Marks, Vincent, °76, °242
Marrack, David, °242
Martin, Donald B., °77, °78
Martin, F. I. R., °404
Martin, Maurice J., °76
Martin-Hernandez, D., °239
Martz, B. L., °330
Matthews, J., °489
McBride, Robert B., °162
McCall, M. S., °494
McConnell, Doreen, °493
McCuiston, Alvin C., °161
McCullough, Campbell C., Jr., °159
McElroy, William T., Jr., °330
McGuckin, Warren F., °242
McIntosh, Hamish W., °76
McLendon, Harold, °159
McMahon, F. Gilbert, °76
Mehnert, Hellmut, °76
Meier, Hans, 12-18, 19-21
Mendel, D., °72
Merola, Lorenzo, 393-395
Meschia, Giacomo, °236
Metz, Robert, °330
Meyer-Hofmann, G., °159
Michaels, George D., 316-319
Miller, A. L., °72
Miller, Emery C., Jr., °403
Miller, Max, °155, °399, °404, °492
Mills, Frank D., °155
Mitchell, Marvin L., 1-6, °77
Moe, H., 253-259
Moeller, J., °75
Molnar, George D., °242
Moloshok, Ralph E., °156, °327
Money, William L., °157
Moore, Clemmie Everly, °159, °331
Morgan, H. E., °403, °405, °406, °492, °493
Moriwaki, Takeshi, °492
Moses, V., °78, °403
Mosovich, Luis L., °243
Mueller, W., °158
Muller, Otto, °489

N

Nabarro, J. D. N., °77
Naide, Meyer, °242, °405
Narahara, H. T., °331
Newcomb, Alvah, °240, °494
Nickerson, Naomi, °155
Nickerson, Rita V., °77, °78
Nicolopoulos, Demetrios, °238, °490
Nordén, Åke, °399
Norton, William S., II, °237
Nowell, John F., °331
Nunn, Arthur S., °325

O

Ohneda, Akira, °73
Oliver, Jean, °489, °493
Onoprienko, Ilarion S., °237
Osler, Mogens, °242
O'Sullivan, D. J., °327, °491
O'Sullivan, John B., °493
Otto, Hellmut, 324-325
Owen, John A., Jr., °242
Ozand, Pinar, °331

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

P

Packer, Henry, 280-285
Page, Otto C., °79
Paloyan, Edward, °405
Panico, Frederick G., °78
Park, C. R., °403, °405, °406, °492, °493
Parker, Gerald W., °492
Parrish, Alvin E., °328
Pastan, Ira, °156
Pauerstein, Carl, °490
Paul, Geoffrey R., °404
Paullada, Juan Jose, °331
Pawan, G. L. S., °71
Payne, R. W., °77
Pearson, Elinor, °325
Pedersen, Jørgen, °242
Pell, Sidney, °160
Penhos, J. C., °158
Penick, S. B., °405
Pennoyer, Douglass C., °494
Penrose, Margaret H., °406
Perkin, Frank S., °160
Peterson, Ruth D., °326
Petersson, Birger, °160, 470-475
Petrelli, F., °243
Pfeiffer, E. F., °326, °400, °405
Pilkington, T. R. E., °404
Pines, Kermit L., °243
Pinter, Gabriel G., °331
Pogády, J., °79
Post, R. L., °406
Priestley, James T., °77, °78
Proper, George, °158
Pyle, Hugh M., °488

R

Rabinowitz, Joseph L., °329
Radding, Robert S., °331
Raeside, J. I., °75
Rafaelsen, Ole J., °243
Randall, Raymond V., °76
Ratner, Irving M., °327
Rauda, Vija, °333
Redding, Tommy W., 85-89
Reddy, D. V. N., °329
Reece, M. W., °162
Regen, D. M., °405, °493
Reid, James, °76
Remein, Quentin R., °332
ReMine, William H., °77, °78
Renold, Albert E., °77, °78, 218-227
Renzi, A. A., °239
Ricketts, Henry T., 211-217, °406
Ries, W., °77
Rifkin, Harold, °406
Robertson, H. Rocke, °76
Robinson, B. H. B., °332
Robinson, Geoffrey C., °493
Root, Howard F., 151-152, °160
Rose, C. F. M., °72
Rose, F. Clifford, °242
Rosenkranz, A., °160
Rossenbeck, H. G., °326
Rothfeld, Edwin L., °160
Ruffin, Julian M., °74
Rupp, Joseph J., °402
Russell, R. O., 1-6
Rutenberg, Joseph, 320-321

S

Saifer, Abraham, °244
Salassa, Robert M., °76
Salter, J. M., 119-121
Sandberg, Herschel, °156, °489
Sanders, Margaret J., 41-45
Sanford, Jay P., °162
Saperstein, Stanley, 122-129
Sarcione, Edward J., °78, °243
Sartorelli, L., °243
Savitsky, J. Philip, °332
Sawyer, T. K., °493
Schaafma, Sj., °241
Schiffmann, Albert, °70, °326
Schlesinger, F. G., °332, °406
Schmid, R., °79
Schnall, Charles, °242, °405
Scholz, Donald A., °77, °78
Schraeder, Jean, °489
Schuster, L., °77
Schwartz, James F., °332
Schwarz, F., °406
Schwarz, K., °161
Schwarz, V., °243
Schwarzkopf, H., °159
Searle, Gordon W., °325
Segal, Stanton, °161, °493
Sehra, K. B., °406
Seige, K., °77
Setty, C. S. N., °240
Shay, Harry, °79
Shelley, Thomas F., °406
Shepardson, Charles R., °492
Sheps, Mindel C., °77, °78
Shiels, William S., °334
Shipp, J. C., 1-6
Shoemaker, William C., °78, °492
Sholiton, Leon J., °407
Shulkind, Martin L., 122-129
Shumacker, H. B., Jr., °71
Shwachman, H., °402
Sibay, T. M., 452-454
Sidbury, James B., Jr., °243, °332
Siliprandi, N., °243
Silverman, C., 351-366
Sims, Ethan A. H., 190-197
Singh, Inder, °406
Sirek, Anna, 375-382
Sirek, Otakar V., 119-121, 375-382
Skillman, Thomas G., 46-51, °157, °406
Smirnov, N. P., °75
Smith, Elspeth B., 345-350
Smith, James M., 312-315
Smith, M. J. H., °78, °403
Smyth, D. H., °489
Snedeker, E. H., °400
Snyder, Harvey B., °72
Sokal, Joseph E., °78, °161, °243
Sokol, E. Marvin, °494
Solomon, David H., °79
Sosa, Dagoberta, 110-113
Sourander, L. B., °403
Spielmann, W., °79
Spitzer, John J., °330
Spolter, Pari D., °333
Sporn, Norman I., °334
Sprague, Randall G., °76
Sprecace, George A., °494
Sproull, D. H., °402
Spurr, Charles L., °403
Stalder, G., °79
Staple, Ezra, °329
Steigerwald, H., °79
Stein, Olga, °241
Steinberg, Arthur G., 269-274
Steiner, Donald F., °333
Steinke, Jurgen, 1-6, °77, °78, 218-227
Stephens, John W., °79
Stolc, V., °79
Stone, Daniel B., °333
Strawitz, J. G., °333
Striebel, James L., °242
Sun, David C. H., °79
Sunderman, F. William, °494
Sunderman, F. William, Jr., °494
Sussman, Marvin B., °407
Sutherland, Anne B., °325
Suzuki, R., °240
Swahn, Bengt, °399
Sweet, Wm. H., °401
Swigart, Richard H., °333

T

Tagnon, R., °326
Takanami, Akira, °73
Tanenbaum, S. W., °325
Tannenhaus, Joseph, °155
Taylor, C. Bruce, °155, °243
Teel, Peter, °78
Thompson, James E., °494
Tjokronegoro, Sutomo, °241
Tomhave, Wesley G., °161
Torosdag, Seta, °328
Traisman, Howard S., °494
Tranquada, Robert E., °79, °488
Tretbar, Harvey A., 455-459
Trueheart, Richard E., °243
Tsitouris, George, °489
Tu, Wu-Hao, °70, °399
Tulloch, J. A., 207-210, 286-288

U

Unger, Roger H., °244, °334, °494

V

Vandam, Leroy D., °157
Van Gastel, C., °332
Van Itallie, Theodore B., °237
Vassalle, Mario, °334
Vaughan, Martha, °494
Veit, Odette, °160
Verner, John V., °74
Vernet, A., 345-350
Visintine, Robert E., 316-319
Volk, Bruno W., °79, °161, °241, °244

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500

W

Wagenvoort, C. A., °406
Walker, Geoffrey, 316-319, °407
Walker, R. S., 275-279
Walker, William F., °78
Wall, Mary, °327
Walters, Waltman, °76
Ward, John A., °398
Wasserman, Albert J., °334
Weber, Jann W., 122-129
Wegner, H., °77
Weil, William B., Jr., °407
Weinberg, Arnold N., °161
Weinges, K. F., °161, °334
Weinhouse, Sidney, °326
Weisenfeld, Shirley, °328
Wendel, Lucille P., °236
Werk, Emile E., Jr., 22-32, °407
West, Edward S., °326
Wheeler, H. O., °489
Wheelock, Frank C., Jr., °407
Wherry, Frances E., 298-302
Whichelow, M. J., °71
White, Priscilla, °159
Whitehouse, Fred W., 58-59
Whitehouse, Michael W., °329
Wiberg, G. S., 198-200, 201-206
Wildberger, Henry L., 211-217
Wilkerson, Hugh L. C., °161, °332
Williams, Capt. Ralph C., Jr., °162
Williams, Robert H., °327, °333
Williams, Wallace R., °162
Williamson, Joseph R., 460-469
Williamson, J. R., °491
Wills, M. R., °162
Wilson, Reginald A., °162
Wilson, T. Hastings, °240
Windom, Robert E., °162
Wiseman, Ralph, Jr., °334
Wohltmann, Hulda J., °402
Wolff, F. W., 351-366
Wolff, M. v., °79
Wolter, J. Reimer, °494
Wood, Francis C., Jr., 218-227
Woodward, Hiram, Jr., °399
Wrenshall, G. A., 304-311
Wright, P. H., °332, °398

Y

Yalow, Rosalyn S., °162, 339-344
Yamashita, Tsuyoshi, 167-174
Yerganian, George, 12-18, 19-21
Yonet, Howard M., °334
Young, D. A. B., °401
Young, F. G., °239
Younger, Mary D., °159

Z

Zachariah, P., °491
Zeigler, R., °400, °405
Zeytinoglu, Ibrahim, °159
Zimmerman, Stanley J., °331
Zollinger, Hans U., °162

DIABETES: VOLUME 10 PAGE NUMBERS BY ISSUE

January-February, 1-84
March-April, 85-166
May-June, 167-252
July-August, 253-338
September-October, 339-420
November-December, 421-500